<SEC-DOCUMENT>0001193125-17-309879.txt : 20171013
<SEC-HEADER>0001193125-17-309879.hdr.sgml : 20171013
<ACCEPTANCE-DATETIME>20171013162032
ACCESSION NUMBER:		0001193125-17-309879
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20171013
DATE AS OF CHANGE:		20171013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAPTYSBIO INC
		CENTRAL INDEX KEY:			0001370053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203828755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-220881
		FILM NUMBER:		171136781

	BUSINESS ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-362-6295

	MAIL ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d453477d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4)<BR> Registration Nos. 333-220881<BR><BR> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">3,000,000 Shares </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g453477g71b77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are
offering&nbsp;3,000,000&nbsp;shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our common stock is listed on The NASDAQ Global Select Market under the symbol
&#147;ANAB&#148;. The last reported sale price of our common stock on The NASDAQ Global Select Market on October&nbsp;12, 2017 was $70.80 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to&nbsp;450,000 additional shares from us at the
public offering price, less the underwriting discounts and commissions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as the term is used in the
Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus, the documents incorporated by reference herein and future filings. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#toc453477_3">Risk Factors</A>&#148; on page 15 of this prospectus.
</B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Price to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Public</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Underwriting</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Discounts and</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Commissions(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proceeds to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AnaptysBio,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Inc.</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$68.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$3.5963</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$64.9037</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$205,500,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$10,788,900</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$194,711,100</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission, any state securities commission nor any other regulatory body has approved or disapproved of these
securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters
expect to deliver the shares on or about&nbsp;October&nbsp;17, 2017. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Credit Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Stifel</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:13pt">
<TD VALIGN="top"><B>Wedbush PacGrow</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Baird</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>SunTrust&nbsp;Robinson&nbsp;Humphrey</B></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The date of this prospectus is&nbsp;October&nbsp;12,
2017. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_1">P<SMALL>ROSPECTUS</SMALL>
S<SMALL>UMMARY</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_2">T<SMALL>HE</SMALL> O<SMALL>FFERING</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_3">R<SMALL>ISK</SMALL> F<SMALL>ACTORS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_4">S<SMALL>PECIAL</SMALL> N<SMALL>OTE</SMALL> R<SMALL>EGARDING</SMALL> F<SMALL>ORWARD
</SMALL><FONT STYLE="white-space:nowrap">-L</FONT><SMALL>OOKING</SMALL> S<SMALL>TATEMENTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_5">M<SMALL>ARKET</SMALL> <SMALL>AND</SMALL> I<SMALL>NDUSTRY</SMALL> D<SMALL>ATA
</SMALL> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_6">U<SMALL>SE</SMALL> <SMALL>OF</SMALL>
P<SMALL>ROCEEDS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_7">D<SMALL>IVIDEND</SMALL> P<SMALL>OLICY</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_8">C<SMALL>APITALIZATION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_9">D<SMALL>ILUTION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_10">C<SMALL>ERTAIN</SMALL> R<SMALL>ELATIONSHIPS</SMALL> <SMALL>AND</SMALL> R<SMALL>ELATED
</SMALL> P<SMALL>ARTY</SMALL> T<SMALL>RANSACTIONS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_11">P<SMALL>RINCIPAL</SMALL>
S<SMALL>TOCKHOLDERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_12">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> C<SMALL>APITAL</SMALL> S<SMALL>TOCK
</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_13">M<SMALL>ATERIAL</SMALL> U.S. F<SMALL>EDERAL</SMALL> I<SMALL>NCOME</SMALL> T<SMALL>AX
</SMALL> C<SMALL>ONSIDERATIONS</SMALL> <SMALL>FOR</SMALL> N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-U.S.</FONT> H<SMALL>OLDERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_14">U<SMALL>NDERWRITING</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_15">L<SMALL>EGAL</SMALL> M<SMALL>ATTERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_16">E<SMALL>XPERTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_17">A<SMALL>DDITIONAL</SMALL>
I<SMALL>NFORMATION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc453477_18">I<SMALL>NCORPORATION</SMALL> <SMALL>OF</SMALL> C<SMALL>ERTAIN</SMALL> I<SMALL>NFORMATION
</SMALL> <SMALL>BY</SMALL> R<SMALL>EFERENCE</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference in this prospectus or to which we have referred you. Neither we
nor the underwriters have authorized anyone to provide you with information that is different. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus or in any document incorporated by
reference herein may only be accurate as of the date hereof or thereof, respectively, regardless of the time of delivery of this prospectus or of any sale of shares of our common stock and the information in any free writing prospectus that we may
provide you in connection with this offering is accurate only as of the date of that free writing prospectus. Our business, financial condition, results of operations and future growth prospects may have changed since those dates. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who come into possession of this prospectus and any applicable free writing prospectus in jurisdictions outside the United States are
required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you
should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth
under the sections &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case included in, or incorporated by reference into, this prospectus. Unless the context
otherwise requires, we use the terms &#147;AnaptysBio,&#148; &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to AnaptysBio, Inc. and our subsidiary. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical stage biotechnology company developing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody product candidates focused on unmet medical needs in inflammation. We develop our product
candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM,
and replicates this natural process of antibody generation <I>in vitro</I>. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading
biopharmaceutical companies where we retain certain development and commercialization rights in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced
wholly-owned antibody programs, ANB020 and ANB019, neutralize therapeutic targets that are genetically associated with severe inflammatory disorders in humans. ANB020 inhibits the activity of the
<FONT STYLE="white-space:nowrap">interleukin-33</FONT> cytokine, or <FONT STYLE="white-space:nowrap">IL-33,</FONT> for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic
dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma. We have completed a Phase 1 trial of ANB020 in healthy volunteers in Australia, the results of which were presented at the 2017 American Academy of Dermatology Annual
Meeting and the American Academy of Allergy, Asthma and Immunology 2017 Annual Meeting in March 2017. We believe the results of this Phase 1 trial demonstrate a favorable safety profile of ANB020, which was well-tolerated and for which no
dose-limiting toxicities were observed, and favorable pharmacodynamic properties of ANB020, where a single dose was sufficient to suppress <FONT STYLE="white-space:nowrap">IL-33</FONT> function for approximately three months post-dosing as measured
by an <I>ex vivo </I>pharmacodynamic assay. We have subsequently completed enrollment of a Phase 2a trial of ANB020 in 12 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic dermatitis
patients, under an approved Clinical Trial Authorisation, or CTA, with the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, and announced <FONT STYLE="white-space:nowrap">top-line</FONT> data from an interim analysis of this trial
in October 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial
enrolled 12 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic dermatitis patients, who were initially administered a single intravenous dose of placebo within 14 days of enrollment,
followed by a single intravenous 300mg dose of ANB020 one week subsequent to placebo. Prior to enrollment in the study, patients were not permitted any systemic or topical medications during a wash-out period. Patients were permitted to take a
monitored amount of topical corticosteroids as rescue therapy during the course of the study. Clinical response was assessed by a number of endpoints, including the improvement of each patient&#146;s Eczema Area Severity Index, or EASI, score, a
tool used to measure the extent and severity of atopic dermatitis, at key time points following ANB020 administration relative to their enrollment baseline. Pruritus, also known as itchiness, as measured by the
<FONT STYLE="white-space:nowrap">5-D</FONT> pruritus scale score, was also assessed for each patient. Exploratory mechanistic biomarkers included granulocyte infiltration and cytokine levels in localized skin lesions measured five days after placebo
administration and five days after ANB020 administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Top-line</FONT> data indicated rapid and
sustained clinical achievement of <FONT STYLE="white-space:nowrap">EASI-50,</FONT> which is 50% or better improvement in EASI score relative to enrollment baseline, in 83% of patients at Day 29, and the 5-D pruritus score was reduced by 32% relative
to enrollment baseline. As early as Day 15 post-ANB020 administration 75% of patients </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reached <FONT STYLE="white-space:nowrap">EASI-50</FONT> and pruritus was reduced by 28%, which was sustained until Day 57 when 75% of patients achieved EASI-50; pruritus was reduced by 22% at Day
57. All 12 patients achieved EASI-50 at one or more timepoints through Day 57 <FONT STYLE="white-space:nowrap">post-ANB020</FONT> administration. Exploratory biomarker assessment indicated reduction of granulocyte infiltration into localized skin
lesions by an average of 30% amongst all patients and 60% among the 10 patients achieving <FONT STYLE="white-space:nowrap">EASI-50</FONT> at 29 days post-ANB020 administration, while exploratory cytokine biomarker levels were below detection limit
and therefore inconclusive. ANB020 was generally well-tolerated by all patients and no severe adverse events have been reported to date. The most frequent treatment-emergent adverse events reported were mild dizziness in two patients subsequent to
placebo dosing, and mild headache in two patients post-ANB020 administration. We plan to report full data from this trial, including results on additional clinical measures, at a medical conference following study completion and further data
analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below summarizes the EASI score improvement and average percent reduction of pruritus scores at various time points
through day 57 of the trial. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g453477g04v98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these data demonstrate
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for ANB020 in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic dermatitis and suggest
that ANB020 may provide meaningful differentiation in terms of patient convenience. As further development in atopic dermatitis, we plan to initiate, during the first half of 2018, a Phase 2b randomized, double-blinded, placebo-controlled study in <FONT
STYLE="white-space:nowrap">200-300</FONT> adults patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> atopic dermatitis to evaluate multi-dose subcutaneous administration of ANB020, with
data expected in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are continuing to enroll, under our Investigational New Drug application, or IND, with the U.S. Food and Drug
Administration, or FDA, a Phase 2a trial of ANB020 with 20 severe adult peanut allergy patients where efficacy is assessed by measuring the cumulative dose of peanut tolerated in an oral food challenge before and after a single dose of ANB020 or
placebo. <FONT STYLE="white-space:nowrap">Top-line</FONT> data are anticipated during the fourth quarter of 2017. We have also initiated enrollment, under a CTA with MHRA, of a Phase&nbsp;2a trial of ANB020 in 24 severe adult eosinophilic asthma
patients, where efficacy will be assessed using improvement in Forced Expiratory Volume in One Second after administration of a single dose of ANB020 or placebo. <FONT STYLE="white-space:nowrap">Top-line</FONT> data are anticipated during the first
half of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB019 inhibits the <FONT STYLE="white-space:nowrap">interleukin-36</FONT> receptor, or
<FONT STYLE="white-space:nowrap">IL-36R,</FONT> for the treatment of rare inflammatory diseases including generalized pustular psoriasis, or GPP, and palmo-plantar pustular psoriasis, or PPP. We are currently
</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conducting, under an approved Clinical Trial Notification, or CTN, a Phase 1 clinical trial in healthy volunteers, where 48 subjects are dosed with ANB019 and 24 are dosed with placebo in single
and multi-dose cohorts at various subcutaneous and intravenously administered dose levels, to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ANB019 and anticipate announcing <FONT STYLE="white-space:nowrap">top-line</FONT>
data from this trial during the fourth quarter of 2017. We subsequently plan to seek regulatory clearance to initiate Phase 2 studies of ANB019 in GPP and PPP patients during 2018. In addition to ANB020 and ANB019, our wholly-owned pipeline includes
novel checkpoint receptor agonist antibodies that we believe are applicable for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated, and have demonstrated efficacy in an animal model of
graft-versus-host disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our wholly-owned antibody programs, multiple AnaptysBio-developed antibody programs have been
advanced under our collaborations to preclinical and clinical milestones. Our collaborations include an immuno-oncology-focused collaboration with TESARO, Inc. and TESARO Development, Ltd., or collectively, TESARO, and an inflammation-focused
collaboration with Celgene Corporation, or Celgene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our TESARO collaboration, TESARO has initiated a registration program under an
IND with the FDA of an AnaptysBio-generated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antagonist antibody <FONT STYLE="white-space:nowrap">(TSR-042)</FONT> in metastatic microsatellite high endometrial
cancer patients. TESARO has completed dose escalation of an AnaptysBio-generated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-TIM-3</FONT></FONT> antagonist antibody <FONT STYLE="white-space:nowrap">(TSR-022)</FONT> in
patients under an IND and has subsequently initiated a combination study of <FONT STYLE="white-space:nowrap">TSR-022</FONT> and <FONT STYLE="white-space:nowrap">TSR-042.</FONT> In addition, TESARO has initiated a Phase 1 study of an
AnaptysBio-generated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-LAG-3</FONT></FONT> antibody <FONT STYLE="white-space:nowrap">(TSR-033),</FONT> and TESARO has initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
preclinical studies for an&nbsp;AnaptysBio-generated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/LAG-3</FONT></FONT> bispecific antibody, which has exhibited similar levels of <FONT STYLE="white-space:nowrap">T-cell</FONT>
activation&nbsp;in vitro&nbsp;as a combination of <FONT STYLE="white-space:nowrap">TSR-042</FONT> and <FONT STYLE="white-space:nowrap">TSR-033.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our collaboration with Celgene, Celgene is advancing two AnaptysBio-generated anti-inflammatory antibody programs. One of these programs
is an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> agonist antibody <FONT STYLE="white-space:nowrap">(CC-90006)</FONT> currently in a Phase 1 trial for psoriasis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through June&nbsp;30, 2017, we have received $73.6&nbsp;million in <FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding from our
collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company is led by a strong management team with deep experience in antibody discovery and development, collaborations,
operations and corporate finance. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed, and will continue to develop, antibody product candidates that leverage emerging insights into biological mechanisms to
treat severe diseases with unmet medical need. The following table summarizes certain key information about our wholly-owned and partnered product candidates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g453477g14h75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced, wholly-owned product candidates are summarized below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ANB020</B> is a potentially
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody that inhibits the activity of <FONT STYLE="white-space:nowrap">IL-33,</FONT> a <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokine
that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. <FONT STYLE="white-space:nowrap">IL-33</FONT> directly mediates release of disease-associated cytokines, which
recruit <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cells that mediate atopic disease. Because ANB020 inhibits <FONT STYLE="white-space:nowrap">IL-33</FONT> function, and acts upstream broadly across the key cell types and cytokines
involved in atopy, we believe that its mechanism has advantages in the treatment of atopic diseases over competing agents that block only a subset of the cytokines responsible for atopic diseases. The role of
<FONT STYLE="white-space:nowrap">IL-33</FONT> signaling in asthma has been recently genetically validated through human studies published in the medical literature. We have completed a Phase 1 trial of ANB020 in healthy volunteers in Australia. We
believe the results of this Phase 1 trial demonstrate a favorable safety profile of ANB020, which was well-tolerated and for which no dose-limiting toxicities were observed, and favorable pharmacodynamic properties of ANB020, where a single dose was
sufficient to suppress <FONT STYLE="white-space:nowrap">IL-33</FONT> function for approximately three months post-dosing as measured by an <I>ex vivo </I>pharmacodynamic assay. We presented these results at the 2017 American Academy of Dermatology
Annual Meeting and the American Academy of Allergy, Asthma and Immunology 2017 Annual Meeting in March 2017. We have subsequently completed enrollment of a Phase 2a trial where a single dose of ANB020 was administered to 12 moderate-to-severe adult
atopic dermatitis patients, under an approved Clinical Trial Authorisation, or CTA, with the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, and, announced top-line data from an interim analysis of this trial in October 2017.
Top-line data indicated rapid and sustained achievement of </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<FONT STYLE="white-space:nowrap">EASI-50,</FONT> which is 50% or better improvement in EASI score relative to enrollment baseline, in 83% of patients at day 29, and reduced the 5-D pruritus
score, which is a measure of itching, by 32% relative to enrollment baseline. As early as Day 15 post-ANB020 administration 75% of patients reached <FONT STYLE="white-space:nowrap">EASI-50</FONT> and pruritus was reduced by 28%, which was sustained
until Day 57 when 75% of patients achieved EASI-50; pruritus was reduced by 22% at Day 57. No severe adverse events have been reported to date under this study. We believe these data demonstrate proof-of-concept for ANB020 in moderate-to-severe
adult atopic dermatitis and provide meaningful differentiation in terms of patient convenience. As further development in atopic dermatitis, we plan to initiate, during the first half of 2018, a Phase 2b randomized, double-blinded,
placebo-controlled study in 200-300 adults patients with moderate-to-severe atopic dermatitis to evaluate multi-dose subcutaneous administration of ANB020, with data expected in 2019. We have also initiated, under our IND a Phase 2a trial of ANB020
in the United States with 20 severe adult peanut allergy patients where efficacy will be assessed by measuring the cumulative dose of peanut tolerated in an oral food challenge before and after a single dose of ANB020 or placebo. We anticipate <FONT
STYLE="white-space:nowrap">top-line</FONT> data from this trial will be available during the fourth quarter of 2017. We have also initiated enrollment, under a CTA with the MHRA, of a Phase 2a trial of ANB020 with 24 severe adult eosinophilic asthma
patients, where efficacy will be assessed using improvement in Forced Expiratory Volume in One Second after administration of a single dose of ANB020 or placebo. <FONT STYLE="white-space:nowrap">Top-line</FONT> data are anticipated during the first
half of 2018. Based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field of atopic dermatitis, we estimate approximately 1.4&nbsp;million adults in the United States are affected by
atopic dermatitis, of which approximately 280,000 are diagnosed with a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> form of this disease, of which 98,000 are believed to be suitable for treatment
with systemic biological therapies. Peanut allergy is the most common cause of food-induced allergy in the United States. Based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the food
allergy field, we estimate approximately 1.7&nbsp;million adults are affected by peanut allergy, of which approximately 600,000 are treated by allergists and approximately 400,000 are at risk for severe reactions and therefore we believe are
suitable for treatment with systemic biological therapies in the United States. We estimate, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders focused on asthma, that asthma affects
approximately 19.0&nbsp;million individuals, of which approximately 1.1 million have severe, persistent occurrence of this respiratory disease in the United States that cannot be controlled by standard-of-care therapy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ANB019</B> is an antibody that inhibits the function of <FONT STYLE="white-space:nowrap">IL-36R,</FONT> which
we are initially developing as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapy for GPP and PPP patients. GPP is a life-threatening, rare, systemic inflammatory disorder that, based
on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field, we estimate affects approximately 3,000 patients in the United States with no approved therapies. Studies have shown that GPP can
be associated in some patients with mutations that lead to abnormally high signaling through the <FONT STYLE="white-space:nowrap">IL-36R,</FONT> which we believe can be addressed by treatment with ANB019 irrespective of whether a GPP patient has a
mutated <FONT STYLE="white-space:nowrap">IL-36R</FONT> signaling pathway. PPP is a <FONT STYLE="white-space:nowrap">non-fatal</FONT> form of pustular psoriasis that we estimate affects approximately 150,000 patients in the United States alone. PPP
is believed to be caused by increased systemic levels of <FONT STYLE="white-space:nowrap">interleukin-36</FONT> resulting in inflammatory pustules on the hands and feet of patients that cause significant inability to stand, walk or do manual work,
which we believe can be addressed by treatment with ANB019. We believe ANB019 is the most advanced therapeutic antibody targeting <FONT STYLE="white-space:nowrap">IL-36R</FONT> in development. We are currently conducting, under an approved CTN, a
Phase 1 clinical trial in healthy volunteers, where 48 subjects are dosed with ANB019 and 24 are dosed with placebo in single and multi-dose cohorts at various subcutaneous and intravenously administered dose levels, to assess the safety,
tolerability, pharmacokinetics and pharmacodynamics of ANB019 and anticipate announcing <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial during the fourth quarter of 2017. We subsequently plan to seek regulatory clearance to
initiate Phase 2 studies of ANB019 in GPP and PPP patients during 2018. We plan to seek FDA </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Orphan Drug Designation for the treatment of GPP and PPP. The FDA may grant Orphan Drug Designation to a drug intended to treat a disease or condition that generally affects fewer than 200,000
individuals in the United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Checkpoint receptor agonist</B> antibodies are being developed by AnaptysBio to multiple different immune checkpoint receptors for the treatment of certain autoimmune diseases where we believe checkpoint receptor
function is insufficiently activated. Known human immune checkpoint receptors include <FONT STYLE="white-space:nowrap">CTLA-4,</FONT> <FONT STYLE="white-space:nowrap">PD-1,</FONT> <FONT STYLE="white-space:nowrap">LAG-3,</FONT> BTLA and TIGIT. We
have discovered certain checkpoint receptor agonist antibodies that have demonstrated efficacy in a rodent model of graft-versus-host disease. We anticipate that, subsequent to regulatory clearance, one of our wholly-owned checkpoint receptor
antibodies will initiate human testing during 2019. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Advantages of Our SHM Platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach to developing novel therapeutic antibody product candidates is based upon SHM, a critical, endogenous process that generates the
essential antibody diversity required to develop a natural immune response to pathogens. Our proprietary antibody generation platform is designed to replicate the natural process of SHM <I>in vitro.</I> Competing antibody discovery technologies
include mouse immunization methodologies, microbial antibody display and human <FONT STYLE="white-space:nowrap">B-cell</FONT> screening. We believe our SHM platform overcomes several key limitations associated with these competing technologies and
has the following competitive advantages: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Diversity against difficult targets.</B> By applying SHM without the constraints of an <I>in vivo</I> environment we are able to generate an unprecedented diversity of antibodies. This enables us to develop
antibodies against human targets that we believe have not otherwise been accessible to other technologies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>High potency.</B> Because our platform generates highly-potent antibodies, we are potentially able to modulate every extracellular target associated with human disease, and believe only small therapeutic doses may be
required to mediate therapeutic effect <I>in vivo</I>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Functional activity selection.</B> Our mammalian cell system simultaneously displays and secretes antibodies during the antibody discovery process, allowing us to incorporate functional assays throughout the process
and focus on product candidates that are optimized for the desired therapeutic activity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Speed.</B> Our platform technology has enabled us to generate therapeutic-grade antibodies and subsequently advance preclinical manufacturing and toxicology studies to the filing of an IND or foreign equivalent,
typically in approximately 2.5 years. We believe this timeline is significantly shorter than conventional antibody discovery approaches based upon mouse immunization and microbial display systems. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Manufacturability.</B> By using mammalian cell display to generate our therapeutic antibodies, we believe our platform mitigates risks associated with antibody expression, formulation and stability during the
antibody generation process. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Collaborations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established collaborations with pharmaceutical and biotechnology companies that have provided us with $73.6&nbsp;million in payments
through June&nbsp;30, 2017. Multiple antibodies, generated by us prior to or during a strategic collaboration, are currently being advanced through development by our collaborators. Our collaborations with TESARO and Celgene are described below:
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TESARO Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our
immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize antibodies generated using our SHM platform consisting of the following antibody product candidates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1</FONT></FONT> Monospecific Antagonist Antibody <FONT STYLE="white-space:nowrap">(TSR-042):&nbsp;Registration</FONT> program initiated for
metastatic microsatellite instability high <FONT STYLE="white-space:nowrap">(MSI-H)</FONT> endometrial cancer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-TIM-3</FONT></FONT> Monospecific Antagonist Antibody <FONT STYLE="white-space:nowrap">(TSR-022):&nbsp;Dose</FONT> escalation completed in Phase 1,
combination trial with <FONT STYLE="white-space:nowrap">TSR-042</FONT> has been initiated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-LAG-3</FONT></FONT> Monospecific Antagonist Antibody <FONT STYLE="white-space:nowrap">(TSR-033):&nbsp;Phase</FONT> 1 trial initiated, and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1/LAG-3</FONT></FONT></FONT> Bispecific Antagonist Antibody:&nbsp;lead candidate identified, <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies <FONT STYLE="white-space:nowrap">on-going.</FONT> </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Celgene Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our collaboration with Celgene, we developed therapeutic antibodies against multiple targets. We granted Celgene the option to obtain
worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis by our
delivery of antibodies meeting certain <FONT STYLE="white-space:nowrap">pre-specified</FONT> parameters pertaining to each target under collaboration. Celgene is currently advancing two AnaptysBio-generated anti-inflammatory antibody programs, where
one of these programs is an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> agonist antibody <FONT STYLE="white-space:nowrap">(CC-90006)</FONT> currently in a Phase 1 trial for psoriasis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Milestones </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate the following
milestones relating to wholly-owned pipeline programs to be attained during the remainder of 2017 and 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Program</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Milestone</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Timing</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#e6f3fa">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#e6f3fa">ANB020&nbsp;(Anti-IL-33)</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">Atopic Dermatitis Phase 2a Top-Line Data</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt" BGCOLOR="#e6f3fa"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Announced October&nbsp;2017</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">Peanut Allergy Phase 2a Top-Line Data</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt" BGCOLOR="#e6f3fa">Q4 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Eosinophilic&nbsp;Asthma&nbsp;Phase&nbsp;2a&nbsp;Top-Line&nbsp;Data</FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt" BGCOLOR="#e6f3fa"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">H1&nbsp;2018</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt" BGCOLOR="#e6f3fa">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#e6f3fa"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ANB019&nbsp;
(anti-IL-36R)</FONT></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">Healthy Volunteer Phase 1 Top-Line Data</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt" BGCOLOR="#e6f3fa">Q4 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000" BGCOLOR="#e6f3fa">GPP Phase 2 Initiation</TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt" BGCOLOR="#e6f3fa">2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" BGCOLOR="#e6f3fa" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#e6f3fa"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PPP Phase 2 Initiation</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" BGCOLOR="#e6f3fa" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#e6f3fa"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2018</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading antibody development company with a pipeline of novel therapeutic antibodies, which is being further expanded by applying our
technology platform to emerging biological targets. The key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Advancing our wholly-owned lead product candidates to clinical milestones.</B> We are conducting clinical trials to assess the safety and efficacy of our wholly-owned pipeline programs, and have completed a Phase 1
trial of ANB020 in healthy volunteers in Australia, which we believe has demonstrated favorable safety and <I>ex vivo</I> pharmacodynamic properties. We are conducting multiple Phase 2a trials of ANB020: top-line results from a Phase 2a trial in
patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic dermatitis were announced in October 2017; <FONT STYLE="white-space:nowrap">top-line</FONT> data from a Phase 2a trial in
patients with severe adult peanut allergy are anticipated in the fourth quarter of 2017; and <FONT STYLE="white-space:nowrap">top-line</FONT> data from a Phase 2a trial in patients with severe adult eosinophilic asthma are anticipated during the
first half of 2018. We are currently conducting, under an approved CTN, a Phase 1 clinical trial in healthy volunteers, where 48 subjects are dosed with ANB019 and 24 are dosed with placebo in single and multi-dose cohorts at various subcutaneous
and intravenously administered dose levels, to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ANB019 and anticipate announcing <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial during the fourth quarter
of 2017. We subsequently plan to seek regulatory clearance to initiate Phase&nbsp;2 studies of ANB019 in GPP and PPP patients during 2018. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Continuing to expand our proprietary pipeline by generating new product candidates using our technology platform.</B> Using our proprietary SHM antibody generation platform, we are able to rapidly develop novel
antibodies against biological emerging targets. Our goal is to continue expanding our wholly-owned new therapeutic antibody program pipeline by innovating one or more novel pipeline antibodies each year. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Identifying emerging opportunities in key therapeutic areas.</B> We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating
biological breakthroughs into <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutic antibodies. Our approach includes translational biology assessments, such as human genetics, <I>ex vivo</I>
tissue pathology and target expression patterns, to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs
for rapid initial efficacy assessment. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Retaining rights to strategic products in key commercial markets.</B> We intend to retain ownership and control of our pipeline programs to key preclinical and clinical data inflection points. We may build sales and
marketing capabilities in the United States with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development
and commercialization. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Financial Update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have not finalized our full financial results for the quarter ended September 30, 2017, we expect to report that we had $116.7 million
of cash and cash equivalents and investments as of September 30, 2017. This amount is preliminary, has not been audited and is subject to change upon completion of our quarterly review. Additional information and disclosures would be required for a
more complete understanding of our financial position and results of operations as of September 30, 2017. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Affecting Us </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks and uncertainties, including those highlighted and incorporated by reference in the section
titled &#147;Risk Factors&#148; immediately following this prospectus summary. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial viability. If we or our collaborators are unable to complete development of
or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have only limited data regarding the safety profile of our wholly-owned product candidates when dosed in humans. Our ongoing and planned clinical trials or those of our collaborators may demonstrate limited efficacy
or reveal significant adverse events, toxicities or other side effects and may result in an efficacy or safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to
commercialize and generate revenue from our product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may not be successful in our efforts to use our technology platform to expand our pipeline of product candidates and develop marketable products. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have only recently commenced clinical development of ANB019 and ANB020 and have no other history of conducting clinical trials or commercializing biotechnology products, which may make it difficult to evaluate the
prospects for our future viability. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our existing collaborations, including those with TESARO and Celgene, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if
these collaborations are not successful, our business could be adversely affected. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The manufacture of biologics is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of
our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for commercial sale, and to date we have not generated any revenue or
profit from product sales. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product
candidates or develop new product candidates. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware in November 2005. Our principal executive offices are located at 10421 Pacific
Center Court, Suite 200, San Diego, California 92121, and our telephone number is (858) <FONT STYLE="white-space:nowrap">362-6295.</FONT> Our website address is www.anaptysbio.com. The information contained on, or that can be accessed through, our
website is not part of, and is not incorporated by reference into, this prospectus. Investors should not rely on any such information in deciding whether to purchase our common stock. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mark &#147;AnaptysBio&#148; is our common law trademark. All other service marks,
trademarks and trade names appearing in this prospectus are the property of their respective owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Implications of Being an Emerging
Growth Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging
growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, enacted in April 2012. An &#147;emerging growth company&#148; may take advantage of reduced reporting requirements that are otherwise applicable to
public companies. These provisions include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use these provisions until the last day of our fiscal year following the fifth anniversary of the closing of our initial public
offering. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a
part and the documents incorporated herein by reference and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might
receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act provides that an emerging growth company
can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we are subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock offered by us </P></TD>
<TD>3,000,000 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares to be<BR> offered by us </P></TD>
<TD>450,000 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock to be outstanding immediately after this offering </P></TD>
<TD><BR>23,289,907 shares (23,739,907&nbsp;shares if the underwriters exercise their option to purchase additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $194.6 million (or approximately $223.8 million if the underwriters exercise their option to purchase additional shares in full), based upon the public offering price of
$68.50 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds that we receive in this offering to fund research and development activities for our clinical development programs, our ongoing preclinical, discovery and research programs, and for
working capital and other general corporate purposes. We may use a portion of the proceeds to acquire other complementary businesses or technologies, although we have no present commitments or agreements to do so. See &#147;Use of Proceeds&#148; for
a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;ANAB&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 20,289,907
shares of our common stock outstanding as of June&nbsp;30, 2017, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,643,180 shares of common stock issuable upon the exercise of options outstanding as of June&nbsp;30, 2017, with a weighted-average exercise price of $10.62 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">96,965 shares of common stock issuable upon the exercise of options granted after June&nbsp;30, 2017, with a weighted-average exercise price of $26.77 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">198,009 shares of our common stock issuable upon exercise of warrants outstanding as of June&nbsp;30, 2017, with an exercise price of $4.55 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,462,014 shares of common stock reserved for future issuance under our stock-based compensation plans as of
June&nbsp;30, 2017, consisting of (a) 1,244,014 shares of common stock reserved for future issuance under our 2017 Equity Incentive Plan and (b) 218,000 shares of common stock reserved for future
</P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
issuance under our 2017 Employee Stock Purchase Plan. Our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan also provide for automatic annual increases in the number of shares
reserved under the plans each year, as more fully described in note 8 of the notes to our unaudited consolidated financial statements included in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended
June&nbsp;30, 2017. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus assumes no exercise of
outstanding options or warrants and no exercise of the underwriters&#146; option to purchase additional shares. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary consolidated statements of operations data presented below for the years ended December&nbsp;31, 2014, 2015 and 2016 are derived
from our audited financial statements incorporated by reference into this prospectus. The selected consolidated statements of operations data for the six months ended June&nbsp;30, 2016 and 2017 and the summary consolidated balance sheet data as of
June&nbsp;30, 2017 have been derived from our unaudited consolidated financial statements incorporated by reference into this prospectus. Our unaudited consolidated financial statements have been prepared on the same basis as our audited financial
statements and, in the opinion of management, reflect all adjustments, which consist only of normal recurring adjustments, necessary for the fair statement of those unaudited consolidated financial statements. The following summary consolidated
financial data should be read with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes incorporated by reference into this prospectus. Our historical
results are not necessarily indicative of the results that may be expected in any future period. The summary financial data in this section are not intended to replace the financial statements and are qualified in their entirety by the financial
statements and related notes incorporated by reference into this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(458</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(867</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on available for sale securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share:(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding:(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note&nbsp;2 to our audited consolidated financial statements incorporated by reference in this prospectus for an explanation of the method used to calculate basic and diluted net income (loss) per common share and
the weighted-average number of shares used in the computation of the per share amounts. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of<BR>June&nbsp;30, 2017<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As<BR>Adjusted(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The as adjusted balance sheet data reflects the sale of&nbsp;3,000,000 shares of common stock by us in this offering, at the public offering price of $68.50 per share, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you
should carefully consider the risks described in Part II, Item&nbsp;1A of our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended June&nbsp;30, 2017 and Part I, Item&nbsp;1A of our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended&nbsp;December 31, 2016, together with all of the other information contained in or incorporated by reference into this prospectus. We cannot assure you that any of the events discussed herein
or therein will not occur. These events could have a material and adverse impact on our business, results of operations, financial condition and cash flows. If that were to happen, the trading price of our common stock could decline, and you could
lose all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to this Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our management will have broad discretion over the use of the proceeds we receive in this offering and might not apply the proceeds in ways that increase
the value of your investment. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion to use the net proceeds from this offering, including for any
of the purposes described in the section entitled &#147;Use of Proceeds,&#148; and you will be relying on the judgment of our management regarding the application of these proceeds. You will not have the opportunity to influence our decisions on how
to use the proceeds, and we may not apply the net proceeds of this offering in ways that increase the value of your investment. Because of the number and variability of factors that will determine our use of the net proceeds from this offering,
their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could harm our business. Pending their use, we intend to invest the net proceeds from this offering in
marketable securities that may include investment-grade interest-bearing securities, money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. These investments may not yield a favorable
return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will suffer immediate and substantial dilution in the net tangible book value of our common stock you purchase in this offering. At the
public offering price of $68.50&nbsp;per share, purchasers of common stock in this offering will experience immediate dilution of $55.46&nbsp;per share in net tangible book value of our common stock. In the past, we issued options, warrants and
other securities to acquire common stock at prices below the public offering price. To the extent these outstanding securities are ultimately exercised, or we issue equity or convertible debt securities in the future at a price less than the public
offering price, investors purchasing common stock in this offering will sustain further dilution. See &#147;Dilution&#148; for a more detailed description of the dilution to new investors in the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference into this prospectus, including the sections entitled &#147;Prospectus
Summary,&#148; &#147;Risk Factors,&#148; &#147;Use of Proceeds,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and &#147;Business&#148;, contains forward-looking statements. The words
&#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;potentially,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148; &#147;plan&#148;
&#147;expect,&#148; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus and the documents incorporated by reference into this prospectus include, among other
things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize antibodies, including our lead product candidates ANB020 for patients with severe allergic and atopic diseases and ANB019 for patients with GPP and PPP; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood that the clinical data generated in any study we are performing or plan to perform in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction will be subsequently accepted by the FDA and its
foreign regulatory authorities outside of the jurisdiction where the study was being performed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and ability of our collaborators to develop and commercialize our partnered product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential benefits and advantages of our product candidates and approaches versus those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to execute on our strategy, including advancing our lead product candidates, identifying emerging opportunities in key therapeutic areas, continuing to expand our wholly-owned pipeline and retaining rights
to strategic products in key commercial markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to obtain and maintain regulatory approvals for ANB020 and ANB019 and our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance and clinical utility of any approved product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and growth potential of the markets for any approved product candidates, and our ability to serve those markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments in the United States, the United Kingdom, Australia and other foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of competing therapies that are or may become available; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract and retain key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our use of the net proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties and assumptions,
including those described or incorporated by reference in &#147;Risk Factors&#148; and elsewhere in this prospectus. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible
for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from
those anticipated or implied in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as predictions of
future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the
forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our
expectations, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the documents incorporated by reference into this prospectus
and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance,
and events and circumstances may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_5"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in or incorporated by reference into this prospectus concerning our industry and the markets
in which we operate, including our general expectations and market position, market opportunity, and market size, is based on information from various sources and on assumptions that we have made that are based on those data and other similar
sources and on our knowledge of the markets for our products. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market
opportunity and market size information included in or incorporated by reference into this prospectus is generally reliable, such information is inherently imprecise. In addition, projections, assumptions and estimates of our future performance and
the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors&#148; and in the documents incorporated by
reference into this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our sale of&nbsp;3,000,000&nbsp;shares of common stock in this offering at the public offering price of
$68.50&nbsp;per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $194.6&nbsp;million, or $223.8&nbsp;million if the underwriters exercise their option to purchase
additional shares in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds we receive from this offering, together with our existing cash,
cash equivalents and investments, to fund research and development activities for our clinical development programs, including, but not limited to, our ongoing and planned clinical trials for ANB020 and ANB019, including related manufacturing costs,
and our ongoing preclinical, discovery and research programs, and for working capital and other general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our
planned use of the net proceeds, we estimate such funds, together with our existing cash, cash equivalents and investments, will be sufficient for us to fund our operating expenses and capital expenditure requirements through at least the next 24
months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business
conditions. As of the date of this prospectus, we cannot predict with any certainty all of the particular uses for the net proceeds or the amounts that we will actually spend on the uses set forth above. We may use a portion of the net proceeds for
the acquisition of, or investment in, technologies, solutions or businesses that complement our business, although we have no present commitments or agreements to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our clinical expenditures and the extent of clinical development may vary significantly depending on numerous
factors, including the status, results and timing of our current and planned preclinical studies and clinical trials, product approval process with the FDA and other regulatory agencies, our current collaborations and any new collaborations we may
enter into with third parties and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected net proceeds of this offering will not be sufficient for us to fund any of our product candidates through regulatory approval,
and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending their use as described above, we intend to invest the net proceeds from this offering in short term and long-term, investment-grade
interest-bearing securities such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKET PRICE OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock has been listed on The NASDAQ Global Select Market under the symbol &#147;ANAB&#148; since January&nbsp;25, 2017. Prior to
that date, there was no public trading market for our common stock. The following table sets forth for the periods indicated the high and low sale prices per share of our common stock as reported on The NASDAQ Global Select Market for the periods
indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fiscal Year 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter (beginning January&nbsp;25, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter (through October&nbsp;12, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2017, the last reported sale price of our common stock on The NASDAQ Global Select Market
was $70.80 per share. As of June&nbsp;30, 2017, we had 95 registered holders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose
shares are held in street name by brokers and other nominees. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings
for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend
on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. In addition, under the terms of our current credit facility, we are prohibited from
paying cash dividends without the consent of Silicon Valley Bank. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents and short-term investments and capitalization as of June&nbsp;30, 2017 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an actual basis; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an as adjusted basis, giving effect to the sale of&nbsp;3,000,000&nbsp;shares of common stock by us in this offering, at the public offering price of $68.50, after deducting the underwriting discounts and commissions
and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table together with &#147;Management&#146;s Discussion
and Analysis of Financial Condition and Results of Operations&#148; and our audited and unaudited consolidated financial statements and related notes incorporated by reference into this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2017<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and par value data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding,
actual and as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 500,000,000 shares authorized, 20,289,907 shares issued and
outstanding, actual; 500,000,000 shares authorized, 23,289,907&nbsp;shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">(59<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(69,083</P></TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom" ALIGN="right">(59<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(69,083</P></TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">314,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 20,289,907 shares
of our common stock outstanding as of June&nbsp;30, 2017, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,643,180 shares of common stock issuable upon the exercise of options outstanding as of June&nbsp;30, 2017, with a weighted-average exercise price of $10.62 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">96,965 shares of common stock issuable upon the exercise of options granted after June&nbsp;30, 2017, with a weighted-average exercise price of $26.77 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">198,009 shares of our common stock issuable upon exercise of warrants for shares of common stock that were outstanding as of June&nbsp;30, 2017, with an exercise price of $4.55 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,462,014 shares of common stock reserved for future issuance under our stock-based compensation plans, consisting of (a) 1,244,014 shares of common stock reserved for future issuance under our 2017 Equity Incentive
Plan and (b) 218,000 shares of common stock reserved for future issuance under our 2017 Employee Stock Purchase Plan. Our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan also provide for automatic annual increases in the number of
shares reserved under the plans each year, as more fully described in the section &#147;Executive Compensation&#151;Employee Benefit and Stock Plans&#148; of our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period
ended June&nbsp;30, 2017 and our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, your interest will be diluted to the extent of the difference between the amount per share paid by
purchasers of shares of common stock in this offering and the as adjusted net tangible book value per share of common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2017, our net tangible book value was approximately $109.2&nbsp;million, or $5.38 per share of common stock. Our net
tangible book value per share represents the amount of our total tangible assets reduced by the amount of our total liabilities and divided by the total number of shares of our common stock outstanding as of June&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to our sale in this offering of&nbsp;3,000,000&nbsp;shares of our common stock at the public offering price of $68.50 per
share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our net tangible book value as of June&nbsp;30, 2017 would have been approximately $303.8 million, or $13.04 per share of common
stock. This represents an immediate increase in net tangible book value of $7.66 per share to our existing stockholders and an immediate dilution of $55.46 per share to investors purchasing shares in this offering, as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of June&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option in full to purchase additional shares, the net tangible book value
per share of our common stock after giving effect to this offering would be $14.03 per share, and the dilution in net tangible book value per share to investors in this offering would be $54.47 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 20,289,907 shares of our common stock outstanding
as of June&nbsp;30, 2017, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,643,180 shares of common stock issuable upon the exercise of options outstanding as of June&nbsp;30, 2017, with a weighted-average exercise price of $10.62 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">96,965&nbsp;shares of common stock issuable upon the exercise of options granted after June&nbsp;30, 2017, with a weighted-average exercise price of $26.77 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">198,009 shares of our common stock issuable upon exercise of warrants for shares of common stock that were outstanding as of June&nbsp;30, 2017, with an exercise price of $4.55 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,462,014 shares of common stock reserved for future issuance under our stock-based compensation plans, consisting of (a) 1,244,014 shares of common stock reserved for future issuance under our 2017 Equity Incentive
Plan and (b) 218,000 shares of common stock reserved for future issuance under our 2017 Employee Stock Purchase Plan. Our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan also provide for automatic annual increases in the number of
shares reserved under the plans each year, as more fully described in the section &#147;Executive Compensation&#151;Employee Benefit and Stock Plans&#148; of our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period
ended June&nbsp;30, 2017 and our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that options or warrants outstanding as of June&nbsp;30, 2017 have been or may be
exercised, or we issue new options or warrants, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even
if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further
dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_10"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We describe below transactions and series of similar transactions since January&nbsp;1, 2014 to which we were a party or will be a party, in
which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts involved exceeded or will exceed $120,000; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our directors, executive officers or beneficial holders of more than 5% of any class of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect
material interest. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described below, there have not been, nor are there any currently proposed, transactions
or series of similar transactions to which we have been or will be a party other than compensation arrangements, which are described where required under the section entitled &#147;Executive Compensation&#148; in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Equity Financings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, we issued an aggregate of 474,001 shares of our Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock
at a purchase price of $4.55 per share, in exchange for the cancellation of secured convertible promissory notes originally issued in July 2013, which as of April 2014 had an aggregate principal and unpaid interest of $2.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock issued to our executive
officers, members of our board of directors and persons who hold more than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:71.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares of<BR>Series <FONT STYLE="white-space:nowrap">C-1</FONT><BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">890,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">890,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alloy Ventures 2005, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">351,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Ventures. Dr.&nbsp;Topper, a member of our Board of Directors, is a General Partner of Frazier Healthcare and may be deemed to
have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi, a former member of our board of directors, is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership
of or pecuniary interest in these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Suria is our President and Chief Executive Officer and is a member of our Board of Directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of our Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock converted automatically into one share of our
common stock upon the closing of our initial public offering. The purchasers of our Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock are entitled to specified registration rights, as described under &#147;Description of
Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Series D Preferred Stock Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, we sold an aggregate of 5,490,973 shares of our Series D convertible preferred stock at a purchase price of $7.42 per share, for
an aggregate cash purchase price of $40.8&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series D convertible preferred stock purchased by our
executive officers, members of our board of directors and persons who hold more than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:71.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares of<BR>Series D<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund, L.P</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,503,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HBM Healthcare Investments (Cayman) Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">159,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert E. Hoffman(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P., both affiliates of Frazier Healthcare. Dr.&nbsp;Topper, a member of our Board of
Directors, is a General Partner of Frazier Healthcare and may be deemed to have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi, a former member of our board of directors, is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership
of or pecuniary interest in these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lydon is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gallagher is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hoffman is our former Chief Financial Officer. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Suria is our President and Chief Executive Officer and is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Londei is our Chief Medical Officer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of our Series D convertible
preferred stock converted automatically into one share of our common stock upon the closing of our initial public offering. The purchasers of our Series D convertible preferred stock are entitled to specified registration rights, as described below
under &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Participation in our Initial Public Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our principal stockholders and their affiliated entities, including stockholders affiliated with certain of our directors,
purchased an aggregate of 1,316,666 shares of our common stock in our initial public offering on January&nbsp;31, 2017 at the initial public offering price of $15.00 per share. The following table summarizes common stock purchased by members of our
board of directors and entities who held more than 5% of our outstanding capital stock at the time of the purchase: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of</B><br><B>Purchased</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>Purchase</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">850,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D.,FRS(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,316,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,749,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 414,373 shares purchased by Biotechnology Value Fund, L.P., 269,019 shares purchased by Biotechnology Value Fund II, L.P., 74,064 shares purchased by Biotechnology Value Trading Fund OS, L.P. and 92,544
shares purchased by MSI BVF SPV LLC. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 311,291 shares purchased by Frazier Healthcare VII, L.P and 88,709 shares purchased by Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P. Dr.&nbsp;Topper, a member of our Board of
Directors, is a General Partner of Frazier Healthcare and may be deemed to have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lydon is a member of our Board of Directors. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended and Restated Investors&#146;
Rights Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an amended and restated investors&#146; rights agreement with certain holders of our
convertible preferred stock, including entities with which certain of our directors are affiliated. These stockholders are entitled to rights with respect to the registration of their shares. For a description of these registration rights, see
&#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers. The indemnification agreements, our
restated certificate of incorporation and our restated bylaws will require us to indemnify our directors to the fullest extent not prohibited by Delaware law. Subject to certain limitations, our restated bylaws also require us to advance expenses
incurred by our directors and officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We adopted a written related person transactions policy that our executive officers, directors, nominees for election as a director,
beneficial owners of more than 5% of our common stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the
review and approval of our audit committee, or a committee composed solely of independent directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. The policy provides that any
request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our common stock or with any of their immediate family members or affiliates in which the amount
involved exceeds $120,000 will be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee will consider the relevant facts and circumstances available and deemed
relevant to the audit committee, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related
person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_11"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock at August&nbsp;31, 2017, and
as adjusted to reflect the sale of common stock in this offering, for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our current directors and executive officers as a group; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, who beneficially owned more than 5% of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of
beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect
to all shares of common stock that they beneficially owned, subject to applicable community property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage
ownership is based on 20,469,570 shares of common stock outstanding as of August&nbsp;31, 2017. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding
all shares of common stock subject to options held by that person or entity that are currently exercisable or that will become exercisable within 60 days of August&nbsp;31, 2017. We did not deem these shares outstanding, however, for the purpose of
computing the percentage ownership of any other person. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o AnaptysBio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, California 92121. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Beneficial Ownership<BR>Prior to this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Beneficial&nbsp;Ownership<BR>After this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Stockholders</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier
Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo Holdings A/S<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,936,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,936,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alloy Ventures 2005, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,904,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,904,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Named Executive Officers</I></B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Moyle Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hollings Renton<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Schmid<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Schoeneck<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James N. Topper, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Anthony Ware, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (11&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,147,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,147,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based on Schedule <FONT STYLE="white-space:nowrap">13-D</FONT> filed by Frazier Healthcare V, L.P. on
February&nbsp;10, 2017. Consists of (a) 2,345,612 shares of common stock held directly by Frazier Healthcare V, L.P., (b) 1,045,031 shares of common stock held directly by Frazier Healthcare VII, L.P., (c) 297,804 shares of common stock held
directly by Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P.. The general partner of Frazier Healthcare V, L.P. is FHM V, L.P., a Delaware limited partnership. The general partner of FHM V, L.P. is FHM V, LLC, a Delaware
limited liability company. The general partner of Frazier Healthcare VII, L.P. and Frazier Healthcare <FONT STYLE="white-space:nowrap">VII-A,</FONT> L.P. is FHM </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
VII, L.P., a Delaware limited partnership. The general partner of FHM VII, L.P. is FHM VII, LLC, a Delaware limited liability company. Dr.&nbsp;Topper, a member of our Board of Directors, Alan
Frazier, Nader Naini, Nathan Every and Patrick Heron are members of FHM V, LLC and FHM VII, LLC and may be deemed to share voting and investment power with respect to the shares held by FHM V, LLC and FHM VII, LLC. The address of Frazier Healthcare
is 601 Union, Two Union Square, Suite 3200, Seattle WA 98101. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Based on Form 4 filed by Novo Holdings A/S on August&nbsp;21, 2017. Consists of (a) 1,936,604 shares of common stock held directly by Novo Holdings A/S. The board of directors of Novo A/S, which is currently comprised
of Sten Scheibye, G&ocirc;ran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared voting and investment power with respect to these shares and may exercise such control only with the support of a majority of the board. As such,
no individual member of the board is deemed to hold any beneficiary ownership in these shares. The address of Novo A/S is Tuborg Havnevej 19, 2900 Hellerup, Denmark. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,282,485 shares of common stock held directly by Alloy Ventures 2005, L.P. The general partner of Alloy Ventures 2005, L.P. is Alloy Ventures 2005, LLC. The managing members of Alloy Ventures 2005, LLC are
Craig Taylor, Doug Kelly John Shoch, Dan Rubin and Tony Di Bona. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Based on Schedule <FONT STYLE="white-space:nowrap">13-G</FONT> filed by Biotechnology Value Fund L.P. on January&nbsp;26, 2017. Consists of (a)&nbsp;907,116 shares of common stock held directly by Biotechnology Value
Fund, L.P., (b)&nbsp;551,019 shares of common stock directly by Biotechnology Value Fund II, L.P., (c)&nbsp;74,064 shares of common stock held directly by Trading Fund OS and (d)&nbsp;372,401 shares of common stock held directly in the Partners
Managed Accounts. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 4,998 shares of common stock held directly by Mr.&nbsp;Suria and (b) 557,332 shares of common stock issuable to Mr.&nbsp;Suria upon the exercise of stock options that are exercisable within 60&nbsp;days
of August&nbsp;31, 2017, of which 102,499 shares were unvested but were early exercisable, as of 60&nbsp;days after August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 2,020 shares of common stock held directly by Dr.&nbsp;Londei and (b)&nbsp;210,918 shares of common stock issuable to Dr.&nbsp;Londei upon the exercise of stock options that are exercisable within
60&nbsp;days of August&nbsp;31, 2017, of which 40,241 shares were unvested but were early exercisable, as of 60&nbsp;days after August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Moyle resigned as our Chief Scientific Officer effective July&nbsp;21, 2017. Consists of (a)&nbsp;30,000 shares of common stock held directly by Mr.&nbsp;Moyle and (b)&nbsp;19,411 shares of common stock
issuable to Mr.&nbsp;Moyle upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 64,296 shares of common stock held directly by Dr.&nbsp;Gallagher and (b)&nbsp;97,722 shares of common stock issuable to Dr.&nbsp;Gallagher upon the exercise of stock options that are exercisable within
60&nbsp;days of August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a) 287,623 shares of common stock held directly by Dr.&nbsp;Lydon, (b)&nbsp;16,483 shares of common stock issuable upon the exercise of a warrant held directly by Dr.&nbsp;Lydon and (c)&nbsp;31,012 shares
of common stock issuable to Dr.&nbsp;Lydon upon the exercise of stock options that are exercisable within 60&nbsp;days of August&nbsp;31, 2017, of which 2,134 shares were unvested but were early exercisable, as of 60&nbsp;days after August&nbsp;31,
2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Represents 51,156 shares of common stock issuable to Mr.&nbsp;Renton upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017, of which 11,652 shares were unvested but were early
exercisable, as of 60 days after August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Represents 42,337 shares of common stock issuable to Mr.&nbsp;Schmid upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017, of which 12,275 shares were unvested but were early
exercisable, as of 60 days after August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Represents 42,337 shares of common stock issuable to Mr.&nbsp;Schoeneck upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017, of which 15,288 shares were unvested but were early
exercisable, as of 60 days after August&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Represents 1,588 shares of common stock issuable to Mr.&nbsp;Ware upon the exercise of stock options that are exercisable within 60 days of August&nbsp;31, 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Includes shares beneficially owned by our executive officers and directors. Consists of (a)&nbsp;4,077,384 shares of common stock, (b) 16,483 shares of common stock issuable upon the exercise of warrants and
(b)&nbsp;1,053,813 shares of common stock issuable upon the exercise of stock options that are exercisable within 60&nbsp;days of August&nbsp;31, 2017, of which 184,089 shares were unvested but early exercisable, as of 60&nbsp;days after
August&nbsp;31, 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dominic G. Piscitelli commenced his employment with us as our Chief Financial Officer in January
2017. As of August&nbsp;31, 2017, Mr.&nbsp;Piscitelli held options to purchase 245,241 shares of our common stock, none of which are exercisable within 60 days of August&nbsp;31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_12"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 500,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of undesignated
preferred stock, $0.001 par value per share. The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete
description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2017, there were 20,289,907 shares of our common stock issued, held by approximately 95 stockholders of record, and
no shares of our preferred stock outstanding. Our board of directors is authorized, without stockholder approval, to issue additional shares of our capital stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dividend
Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common
stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. See
&#147;Dividend Policy&#148; above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voting Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not
provided for cumulative voting for the election of directors in our restated certificate of incorporation. Accordingly, pursuant to our restated certificate of incorporation, holders of a majority of the shares of our common stock can elect all of
our directors. Our restated certificate of incorporation establishes a classified board of directors, divided into three classes with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with
the other classes continuing for the remainder of their respective three-year terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>No Preemptive or Similar Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Right to Receive Liquidation Distributions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally available for distribution to our
stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of
and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to
establish from time to time the number of shares to be included in each series and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by
our stockholders. Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders.
Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing
flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our
common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
June&nbsp;30, 2017, we had outstanding warrants to purchase an aggregate of 198,009 shares of our common stock, with an exercise price of $4.55 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Options </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
June&nbsp;30, 2017, we had outstanding options to purchase an aggregate of 2,643,180 shares of our common stock, with a weighted-average exercise price of $10.62. Subsequent to June&nbsp;30, 2017, we granted stock options to purchase
96,965&nbsp;shares of common stock, with a weighted-average exercise price of $26.77&nbsp;per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of our Amended and Restated Investor Rights Agreement, the holders of approximately 9,240,026 shares of our common stock
are entitled to rights with respect to the registration of these shares under the Securities Act, as described below. We refer to these shares collectively as registrable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Demand Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any point, the holders of at least a majority of the then-outstanding registrable securities may make a written request to us for the
registration of any of the registrable securities under the Securities Act. Within 30 days of such request, we are obligated to provide written notice of such request to all stockholders to file a registration statement under the Securities Act
covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any other holders. We are only required to file two registration
statements that are declared effective upon exercise of these demand registration rights. We may postpone taking action with respect to such filing not more than once during any <FONT STYLE="white-space:nowrap">12-month</FONT> period for a total
period of not more than 60 days if our board of directors determines in its good faith judgment that it would be seriously detrimental to us and our stockholders for such registration statement to be effected at such time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any holder of then-outstanding registrable securities can request that we register all or part of their shares on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and if the aggregate price to the public of the shares offered is at least $2,000,000. The stockholders may
only require us to effect two registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> in a <FONT STYLE="white-space:nowrap">12-month</FONT> period. We may postpone taking action with respect to such filing once during any <FONT
STYLE="white-space:nowrap">12-month</FONT> period for a total cumulative period of not more than 90 days if our board of directors determines in its good faith judgment that the filing would be materially detrimental to us and our stockholders. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Piggyback Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, holders of registrable securities were entitled to, and the necessary percentage of holders waived, their
rights to notice of this offering and to include their registrable securities in this offering. If we register any of our securities for public sale in another offering, holders of registrable securities will have the right to include their shares
in the registration statement. However, this right does not apply to a registration relating to employee benefit plans, a registration relating to a corporate reorganization or a registration of only common stock issuable upon conversion of debt
securities that are also being registered. We have the right to terminate any registration we have initiated before the effective date of such registration, whether or not any holder has elected to include registrable securities in such
registration. The underwriters of any underwritten offering will have the right to limit the number of shares registered by these holders if they determine in good faith that marketing factors require limitation, in which case the number of shares
to be registered will be apportioned pro rata among these holders, according to the total amount of securities entitled to be included by each holder, or in a manner mutually agreed upon by the holders. However, in any underwriting not in connection
with an initial public offering, the number of shares to be registered by these holders cannot be reduced below 30% of the total shares covered by the registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expenses of Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally will pay all expenses, other than underwriting discounts and commissions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Expiration of Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights described above will expire, with respect to any particular holder of these rights, on the earlier of the fifth
anniversary of the closing of our initial public offering, a merger, consolidation, sale or disposition of our company or a sale by a holder of equity securities representing at least a majority of the voting power of our company, or when that
holder can sell all of its registrable securities in a three-month period without restriction under Rule 144 of the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our restated certificate of incorporation and our restated bylaws could have the effect of delaying, deferring
or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control
of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to
acquire us because negotiation of these proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law regulating corporate takeovers. In general,
Section&nbsp;203 prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, but </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
not the outstanding voting stock owned by the interested stockholder, (1)&nbsp;shares owned by persons who are directors and also officers and (2)&nbsp;shares owned by employee stock plans in
which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written
consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in
a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a
corporation&#146;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section&nbsp;203 may also
discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Restated
Certificate of Incorporation and Restated Bylaw Provisions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our restated bylaws include
a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Board of Directors Vacancies.</I> Our restated certificate of incorporation and restated bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the
number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of
directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Classified Board.</I> Our restated certificate of incorporation and restated bylaws provide that our board is classified into three classes of directors, each with staggered three-year terms. A third party may be
discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Stockholder Action; Special Meetings of Stockholders.</I> Our restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special
meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated
bylaws. Further, our restated bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairman of our board of directors, our Chief Executive Officer or our President, thus prohibiting
a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal
of directors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations.</I> Our restated bylaws
provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify
certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our
annual meeting of stockholders </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the
acquirer&#146;s own slate of directors or otherwise attempting to obtain control of our company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>No Cumulative Voting.</I> The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#146;s certificate of
incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws do not provide for cumulative voting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Directors Removed Only for Cause.</I> Our restated certificate of incorporation provides that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Amendment of Charter Provisions.</I> Any amendment of the above provisions in our restated certificate of incorporation would require approval by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT>
of our outstanding common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Issuance of Undesignated Preferred Stock.</I> Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and
preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt
to obtain control of us by merger, tender offer, proxy contest or other means. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Choice of Forum.</I> Our restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf;
any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our restated certificate of incorporation or our restated bylaws; or any action asserting a claim
against us that is governed by the internal affairs doctrine. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock Transfer and Trust Company, LLC. The transfer agent&#146;s address is
6201&nbsp;15th Avenue, Brooklyn, New York 11219, and its telephone number is <FONT STYLE="white-space:nowrap">(800)&nbsp;937-5449.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_13"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section summarizes the material U.S. federal income tax considerations
relating to the acquisition, ownership and disposition of our common stock acquired in this offering by <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holders&#148; (as defined below). This summary does not provide a complete analysis of all
potential U.S. federal income tax considerations relating thereto. The information provided below is based upon provisions of the Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, administrative
rulings and judicial decisions currently in effect. These authorities may change at any time, possibly retroactively, or the Internal Revenue Service, or IRS, might interpret the existing authorities differently. In either case, the tax
considerations of owning or disposing of our common stock could differ from those described below. As a result, we cannot assure you that the tax consequences described in this discussion will not be challenged by the IRS or will be sustained by a
court if challenged by the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not address the tax considerations arising under the laws of any <FONT
STYLE="white-space:nowrap">non-U.S.,</FONT> state or local jurisdiction, or under U.S. federal gift and estate tax laws, except to the limited extent provided below. In addition, this discussion does not address tax considerations applicable to an
investor&#146;s particular circumstances or to investors that may be subject to special tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies or other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships or other entities treated as partnerships or pass-through entities for U.S. federal tax purposes (or investors in such entities); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">corporations that accumulate earnings to avoid U.S. federal income tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax or the Medicare contribution tax on net investment income; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations or passive foreign investment companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who acquired our common stock as compensation for services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dealers in securities or currencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">traders in securities that elect to use a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion transaction&#148; or other risk reduction transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, for investment purposes); or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if a partnership or entity classified as a partnership or other pass-through entity for U.S. federal income tax purposes is a
beneficial owner of our common stock, the tax treatment of a partner in the partnership or an owner of the entity will depend upon the status of the partner or other owner and the activities of the partnership or other entity. Accordingly, this
summary does not address tax considerations applicable to partnerships that hold our common stock, and partners in such partnerships should consult their tax advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">INVESTORS CONSIDERING THE PURCHASE OF OUR COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL
INCOME AND ESTATE TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE CONSEQUENCES OF FOREIGN, STATE OR LOCAL LAWS, AND TAX TREATIES. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Defined </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this summary, a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; is any beneficial owner of our common
stock, other than a partnership, that is not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state therein or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust if it (i)&nbsp;is subject to the primary supervision of a U.S. court and one of more U.S. persons have authority to control all substantial decisions of the trust or (ii)&nbsp;has a valid election in effect
under the applicable Treasury regulations to be treated as a U.S. person; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate whose income is subject to U.S. income tax regardless of source. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> citizen who is an individual, you may, in some cases, be deemed to be a resident alien, as opposed to a nonresident alien, by virtue of being present in the United States for at least 31 days in the
calendar year and for an aggregate of at least 183 days during a three-year period ending in the current calendar year. Generally, for this purpose, all the days present in the current year, <FONT STYLE="white-space:nowrap">one-third</FONT> of the
days present in the immediately preceding year, and <FONT STYLE="white-space:nowrap">one-sixth</FONT> of the days present in the second preceding year are counted. Resident aliens are subject to U.S. federal income tax as if they were U.S. citizens.
Such an individual is urged to consult his or her own tax advisor regarding the U.S. federal income tax consequences of the ownership or disposition of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dividends </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
expect to declare or make any distributions on our common stock in the foreseeable future. If we do pay dividends on shares of our common stock, however, such distributions will constitute dividends for U.S. federal income tax purposes to the extent
paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied
against and reduces, but not below zero, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s adjusted tax basis in shares of our common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of our
common stock. See &#147;&#151;Sale of Common Stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any dividend paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
on our common stock that is not effectively connected with a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or business in the United States will generally be subject to U.S. withholding tax at a 30% rate. The
withholding tax might apply at a reduced rate, however, under the terms of an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence. You should consult your
tax advisors regarding your entitlement to benefits under a relevant income tax treaty. Generally, in order for us or our paying agent to withhold tax at a lower treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must certify its
entitlement to treaty benefits. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally can meet this certification requirement by providing a Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or Form <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or any successor of such forms) or appropriate substitute form to us or our paying agent. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds the stock through a financial
institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate documentation to the agent. The holder&#146;s agent will then be required to provide certification to us or our paying agent, either
directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, you may obtain a refund or credit of any excess amounts withheld by filing an appropriate claim for a refund
with the IRS in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that are effectively
connected with a U.S. trade or business conducted by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, and if required by an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#146;s country of residence, are attributable to a permanent establishment maintained by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, are not subject to U.S. withholding tax. To obtain this exemption, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder must provide us or our paying agent with an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> properly certifying such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same
graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition to being taxed at graduated tax rates, dividends received by corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders that are effectively
connected with a U.S. trade or business of the corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable tax treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See also the section below titled &#147;&#151;Foreign Account Tax Compliance Act&#148; for additional withholding rules that may apply to
dividends paid to certain foreign financial institutions or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sale of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding Backup Withholding and Information Reporting and the Foreign Account Tax Compliance Act, <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders will generally not be subject to U.S. federal income tax on any gains realized on the sale, exchange or other disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain (i)&nbsp;is effectively connected with the conduct by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of a U.S. trade or business and (ii)&nbsp;if required by an applicable income tax treaty between
the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence, is attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United
States (in which case the special rules described below apply); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual who is present in the United States for 183 days or more in the taxable year of the sale, exchange or other disposition of our common stock,
and certain other requirements are met (in which case the gain would be subject to a flat 30% tax, or such reduced rate as may be specified by an applicable income tax treaty, which may be offset by U.S. source capital losses, even though the
individual is not considered a resident of the United States); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules of the Foreign Investment in Real Property Tax Act, or FIRPTA, treat the gain as effectively connected with a U.S. trade or business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FIRPTA rules may apply to a sale, exchange or other disposition of our common stock if we are, or were within the shorter of the five-year
period preceding the disposition and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, a &#147;U.S. real property holding corporation,&#148; or USRPHC. In general, we would be a USRPHC if interests in U.S. real
estate comprised at least half of the value of our business assets. We do not believe that we are a USRPHC and we do not anticipate becoming one in the future. Even if we become a USRPHC, gain realized by a Non U.S. Holder on a disposition of our
common stock will not be subject to U.S. federal income tax so long as (1)&nbsp;the Non U.S. Holder owned, directly, indirectly or constructively, no more than five percent of our common stock at all times within the shorter of (i)&nbsp;the five
year period preceding the disposition or (ii)&nbsp;the holder&#146;s holding period and (2)&nbsp;our common stock is regularly traded on an established securities market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any gain from the sale, exchange or other disposition of our common stock, (i)&nbsp;is effectively connected with a U.S. trade or business
conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and (ii)&nbsp;if required by an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of
residence, is attributable to a permanent establishment maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, then the gain generally will be subject to U.S. federal income tax at the same graduated rates
applicable to U.S. persons, net of certain deductions and credits. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a corporation, under certain circumstances, that portion of its earnings and profits that is effectively connected
with its U.S. trade or business, subject to certain adjustments, generally would be subject also to a &#147;branch profits tax.&#148; The branch profits tax rate is 30%, although an applicable income tax treaty between the United States and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence might provide for a lower rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>U.S. Federal Estate Tax </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estates of nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a
U.S. corporation, our common stock will be U.S. situs property and therefore will be included in the taxable estate of a nonresident alien decedent, unless an applicable estate tax treaty between the United States and the decedent&#146;s country of
residence provides otherwise. The terms &#147;resident&#148; and &#147;nonresident&#148; are defined differently for U.S. federal estate tax purposes than for U.S. federal income tax purposes. Investors are urged to consult their own tax advisors
regarding the U.S. federal estate tax consequences of the ownership or disposition of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Backup Withholding and
Information Reporting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Code and the Treasury regulations require those who make specified payments to report the payments to the
IRS. Among the specified payments are dividends and proceeds paid by brokers to their customers. The required information returns enable the IRS to determine whether the recipient properly included the payments in income. This reporting regime is
reinforced by &#147;backup withholding&#148; rules. These rules require the payors to withhold tax from payments subject to information reporting if the recipient fails to cooperate with the reporting regime by failing to provide his taxpayer
identification number to the payor, furnishing an incorrect identification number, or failing to report interest or dividends on his returns. The backup withholding tax rate is currently 28%. The backup withholding rules do not apply to payments to
corporations, whether domestic or foreign, provided they establish such exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of dividends on common stock generally will not be subject to backup withholding, and payments of proceeds made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders by a broker upon a
sale of common stock will not be subject to information reporting or backup withholding, in each case so long as the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder certifies its nonresident status (and we or our paying agent do not have
actual knowledge or reason to know the holder is a U.S. person or that the conditions of any other exemption are not, in fact, satisfied) or otherwise establishes an exemption. The certification procedures to claim treaty benefits described under
&#147;&#151;Dividends&#148; will generally satisfy the certification requirements necessary to avoid the backup withholding tax. We must report annually to the IRS any dividends paid to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
and the tax withheld, if any, with respect to these dividends. Copies of these reports may be made available to tax authorities in the country where the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treasury regulations, the payment of proceeds from the disposition of shares of our common stock by a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder made to or through a U.S. office of a broker generally will be subject to information reporting and backup withholding unless the beneficial owner certifies, under penalties of perjury, among
other things, its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (and the broker does not have actual knowledge or reason to know the holder is a U.S. person) or otherwise establishes an exemption. The payment of proceeds from
the disposition of shares of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder made to or through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker generally will not be subject to backup withholding
and information reporting, except as noted below. Information reporting, but not backup withholding, will apply to a payment of proceeds, even if that payment is made outside of the United States, if you sell our common stock through a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a U.S. person (including a foreign branch or office of such person); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;controlled foreign corporation&#148; for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign partnership if at any time during its tax year (a)&nbsp;one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or
(b)&nbsp;the foreign partnership is engaged in a U.S. trade or business; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unless the broker has documentary evidence that the beneficial owner is a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and certain other conditions are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no actual knowledge or reason to know to the contrary). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld from a payment to a holder of common stock under the backup withholding
rules can be credited against any U.S. federal income tax liability of the holder and may entitle the holder to a refund, provided that the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. federal withholding tax of 30% may apply to dividends and the gross proceeds of a disposition of our common stock paid to a foreign
financial institution (as specifically defined by the applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial
information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). This U.S. federal withholding tax of 30% will
also apply to dividends and the gross proceeds of a disposition of our common stock paid to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent with either a certification that it
does not have any substantial direct or indirect U.S. owners or provides information regarding direct and indirect U.S. owners of the entity. The 30% federal withholding tax described in this paragraph cannot be reduced under an income tax treaty
with the United States or by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or similar documentation. The withholding tax described above will not apply if the foreign financial institution or
<FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from the rules. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits
of such taxes. Holders should consult with their own tax advisors regarding the possible implications of the withholding described herein. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the
United States governing FATCA may be subject to different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding provisions described above generally will apply to
proceeds from a sale or other disposition of common stock if such sale or other disposition occurs on or after January&nbsp;1, 2019 and currently apply to payments of dividends on our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX CONSEQUENCES
OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_14"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions contained in an underwriting agreement dated October&nbsp;12, 2017, we have agreed to sell to
the underwriters named below, for whom Credit Suisse Securities (USA) LLC, Jefferies LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated are acting as representatives, the following respective numbers of shares of common stock: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:43.10pt; font-size:8pt; font-family:Times New Roman"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Baird &amp; Co. Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SunTrust Robinson Humphrey, Inc.&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the underwriters are obligated to purchase all the shares of common
stock in the offering if any are purchased, other than those shares covered by the option to purchase additional shares described below. The underwriting agreement also provides that if an underwriter defaults the purchase commitments of <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the offering may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the
underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase on a pro rata basis up to&nbsp;450,000 additional shares at the public offering price less the underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the shares of common stock initially at the public offering price on the cover page of this prospectus and
to selling group members at that price less a selling concession of $2.1578&nbsp;per share. After the public offering the underwriters may change the public offering price<B> </B>and concession and discount to broker/dealers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the compensation we will pay: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With Option<BR>to Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting Discounts and Commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.5963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.5963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,788,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,407,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our out of pocket expenses for this offering will be approximately $434,060. We have also
agreed to reimburse the underwriters for up to $35,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. In addition, the underwriters have agreed to reimburse
us for certain expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our executive officers and directors (other than Dr. Lydon) have agreed with the underwriters that, for a
period of 90 days after the date of this prospectus, and Dr. Lydon and entities affiliated with Frazier Healthcare have agreed with the underwriters that, for a period of 60 days after the date of this prospectus, subject to certain exceptions, we
and they will not (1)&nbsp;offer, sell, pledge, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of (or enter
into any transaction which is designed to, or might reasonably be expected to, result in the disposition), directly or indirectly, including the filing (or participation in the filing) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the SEC of a registration statement under the Securities Act to register, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common
stock or warrants or other rights to acquire shares of our common stock of which such officer, director or holder is now, or may in the future become, the beneficial owner (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT>
under the Exchange Act), or (2)&nbsp;enter into any swap or other derivatives transaction that transfers to another, in whole or in part, directly or indirectly, any of the economic benefits or risks of ownership of such common stock, securities,
warrants or other rights to acquire common stock, whether any such transaction described in clause&nbsp;(1) or (2) above is to be settled by delivery of common stock or other securities, in cash or otherwise, or (3)&nbsp;publicly disclose the
intention to enter into any transaction described in clause&nbsp;(1) or (2) above, except with the prior written consent of Credit Suisse Securities (USA) LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions on our executive officers and directors and their affiliates above do not apply to the following, subject to certain
limitations set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities as a bona fide gift; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of securities to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory or any member of the immediate family of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> signatory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities to affiliates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> signatory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of shares of our common stock or securities convertible or exchangeable into shares of our common stock acquired in open market purchases after the closing of this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entry into any trading plan established pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exercise of options, warrants or other rights to acquire shares of common stock in accordance with their terms pursuant to an employee benefit plan, option, warrant or other right; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers pursuant to a court order or settlement agreement related to the distribution of assets in connection with the dissolution of a marriage or civil union; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers to us pursuant to agreements under which we have the option to repurchase such shares or a right of first refusal with respect to transfers of such shares upon termination of service of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> signatory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers by certain stockholders of shares purchased in this offering; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of shares of our common stock or any security convertible into or exercisable or exchangeable for common stock pursuant to a liquidation, tender offer, merger, consolidation or similar transaction that results
in all of our stockholders having the right to exchange their securities for cash, securities or other property. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We<I>
</I>have agreed to indemnify the underwriters against liabilities under the Securities Act, or contribute to payments that the underwriters may be required to make in that respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Global Select Market under the symbol &#147;ANAB.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering
transactions and penalty bids and passive market making in accordance with Regulation M under the Securities Exchange Act of 1934, as amended, or the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not
exceed a specified maximum. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Over-allotment involves sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase, which creates a syndicate short position. The short position may be either a
covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of additional shares that they have the option to purchase. In a naked short
position, the number of shares involved is greater than the number of additional shares that they have the option to purchase. The underwriters may close out any covered short position by either exercising their option to purchase additional shares
and/or purchasing shares in the open market. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Syndicate covering transactions involve purchases of the common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to
close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares through their option. If the
underwriters sell more shares than could be covered by the option to purchase additional shares, a naked short position, the position can only be closed out by buying shares in the open market. A naked short position is more likely to be created if
the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing or syndicate covering
transaction to cover syndicate short positions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In passive market making, market makers in the common stock who are underwriters or prospective underwriters may, subject to limitations, make bids for or purchases of our common stock until the time, if any, at which a
stabilizing bid is made. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These stabilizing transactions, syndicate covering transactions and penalty bids may have the
effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of the common stock. As a result the price of our common stock may be higher than the price that might otherwise exist in
the open market. These transactions may be effected on The NASDAQ Global Select Market or otherwise and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on the web sites maintained by one or more of the underwriters, or selling group
members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate a number of shares to underwriters and selling
group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full-service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. These investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Selling Restrictions: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than in the United States,
no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under
circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the
offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is
unlawful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is not intended to constitute an offer or solicitation to purchase or invest in the securities described herein. The securities
may not be publicly offered, sold or advertised, directly or indirectly, in, into or from Switzerland and will not be listed on the SIX Swiss Exchange or on any other exchange or regulated trading facility in Switzerland. Neither this document nor
any other offering or marketing material relating to the securities constitutes a prospectus as such term is understood pursuant to article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the
listing rules of the SIX Swiss Exchange or any other regulated trading facility in Switzerland, and neither this document nor any other offering or marketing material relating to the securities may be publicly distributed or otherwise made publicly
available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, nor the Company
nor the securities have been or will be filed with or approved by any Swiss regulatory authority. The securities are not subject to the supervision by any Swiss regulatory authority, e.g., the Swiss Financial Markets Supervisory Authority FINMA
(FINMA), and investors in the securities will not benefit from protection or supervision by such authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the
European Economic Area </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive
(each, a Relevant Member State), each underwriter represents and agrees that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, it has not made and will not make an offer of
securities which are the subject of the offering contemplated by this prospectus to the public in that Relevant Member State other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall require us or any underwriter to publish a prospectus pursuant to Article&nbsp;3 of the
Prospectus Directive. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to
any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State, the expression Prospectus Directive means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State),
and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the underwriters severally represents warrants and agrees as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the
Financial Services and Markets Act 2000 (FSMA) received by it in connection with the issue or sale of the securities in circumstances in which Section&nbsp;21 of the FSMA does not apply to us; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">it has complied with, and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Canadian Residents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Resale Restrictions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of shares of common stock offered hereby in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British
Columbia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares offered hereby in
Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable
Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Representations of Canadian Purchasers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By purchasing shares of common stock offered hereby in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to
us and the dealer from whom the purchase confirmation is received that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is entitled under applicable provincial securities laws to purchase the shares without the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as
defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;</FONT><I>Prospectus Exemptions</I>, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is a &#147;permitted client&#148; as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103&#151;</FONT><I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>,
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where required by law, the purchaser is purchasing as principal and not as agent, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser has reviewed the text above under Resale Restrictions. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of
Interest </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canadian purchasers are hereby notified that the underwriters are relying on the exemption set out in section 3A.3 or
3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;</FONT><I>Underwriting Conflicts</I><I></I>&nbsp;from having to provide certain conflict of interest disclosure in this document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Statutory Rights of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the
offering memorandum (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Enforcement of Legal Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible
for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to
satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation and Eligibility for Investment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canadian purchasers of shares of common stock offered hereby should consult their own legal and tax advisors with respect to the tax
consequences of an investment in the shares in their particular circumstances and about the eligibility of the shares for investment by the purchaser under relevant Canadian legislation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in France </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this prospectus nor any other offering material relating to the securities described in this prospectus has been submitted to the
clearance procedures of the Autorit&eacute; des March&eacute;s Financiers or of the competent authority of another member state of the European Economic Area and notified to the Autorit&eacute; des March&eacute;s Financiers. The securities have not
been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to the securities has been or will be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the relevant member state has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us for any such offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">released, issued, distributed or caused to be released, issued or distributed to the public in France; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">used in connection with any offer for subscription or sale of the securities to the public in France. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such offers, sales and distributions will be made in France only: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to qualified investors (<I>investisseurs qualifi&eacute;s) </I>and/or to a restricted circle of investors (<I>cercle restreint d&#146;investisseurs</I>), in each case investing for their own account, all as defined in,
and in accordance with articles <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.411-1,</FONT> <FONT STYLE="white-space:nowrap">D.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.734-1,</FONT> <FONT
STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the French Code mon&eacute;taire et financier; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to investment services providers authorized to engage in portfolio management on behalf of third parties; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in a transaction that, in accordance with article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.411-2-II-1&deg;</FONT></FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-or-2&deg;</FONT></FONT> <FONT STYLE="white-space:nowrap">-or</FONT> 3&deg; of the French Code mon&eacute;taire et financier and article <FONT STYLE="white-space:nowrap">211-2</FONT>
of the General Regulations (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) of the Autorit&eacute; des March&eacute;s Financiers, does not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be resold directly or indirectly, only in compliance with articles <FONT
STYLE="white-space:nowrap">L.411-1,</FONT> <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> through <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the French Code mon&eacute;taire et financier. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Republic
of Italy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of securities has not been registered with the <I>Commissione Nazionale per le Societ&agrave; e la Borsa
</I>(&#147;CONSOB&#148;) pursuant to Italian securities legislation and, accordingly, no securities may be offered, sold or delivered, nor copies of this prospectus supplement, the accompanying prospectus or any other documents relating to the
securities may not be distributed in Italy except: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to &#147;qualified investors&#148;, as referred to in Article 100 of Legislative
Decree No.&nbsp;58 of 24&nbsp;February 1998, as amended (the &#147;Decree No.&nbsp;58&#148;) and defined in Article 26, paragraph 1, letter d) of CONSOB Regulation No.&nbsp;16190 of 29&nbsp;October 2007, as amended (&#147;Regulation
No.&nbsp;16190&#148;) pursuant to Article <FONT STYLE="white-space:nowrap">34-ter,</FONT> paragraph 1, letter. b) of CONSOB Regulation No.&nbsp;11971 of 14&nbsp;May 1999, as amended (&#147;Regulation No.&nbsp;11971&#148;); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in any other circumstances where an express exemption from compliance with the offer restrictions applies, as provided under Decree
No.&nbsp;58 or Regulation No.&nbsp;11971. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer, sale or delivery of the securities or distribution of copies of this prospectus
supplement, the accompanying prospectus or any other documents relating to the securities in the Republic of Italy must be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) made by
investment firms, banks or financial intermediaries permitted to conduct such activities in the Republic of Italy in accordance with Legislative Decree No.&nbsp;385 of 1&nbsp;September 1993, as amended (the &#147;Banking Law&#148;), Decree
No.&nbsp;58 and Regulation No.&nbsp;16190 and any other applicable laws and regulations; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in compliance with Article 129 of the
Banking Law, and the implementing guidelines of the Bank of Italy, as amended; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) in compliance with any other applicable
notification requirement or limitation which may be imposed, from time to time, by CONSOB or the Bank of Italy or other competent authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that, in accordance with Article <FONT STYLE="white-space:nowrap">100-bis</FONT> of Decree No.&nbsp;58, where no exemption from
the rules on public offerings applies, the subsequent distribution of the securities on the secondary market in Italy must be made in compliance with the public offer and the prospectus requirement rules provided under Decree No.&nbsp;58 and
Regulation No.&nbsp;11971. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, securities which are initially offered and placed in Italy or abroad to qualified investors only
but in the following year are regularly (&#147;<I>sistematicamente</I>&#148;) distributed on the secondary market in Italy to <FONT STYLE="white-space:nowrap">non-qualified</FONT> investors become subject to the public offer and the prospectus
requirement rules provided under Decree No.&nbsp;58 and Regulation No.&nbsp;11971. Failure to comply with such rules may result in the sale of the securities being declared null and void and in the liability of the intermediary transferring the
securities for any damages suffered by such <FONT STYLE="white-space:nowrap">non-qualified</FONT> investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Germany </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a Prospectus Directive-compliant prospectus in accordance with the German Securities
Prospectus Act (<I>Wertpapierprospektgesetz</I>) and does therefore not allow any public offering in the Federal Republic of Germany (&#147;Germany&#148;) or any other Relevant Member State pursuant to &#167;&nbsp;17 and &#167;&nbsp;18 of the German
Securities Prospectus Act. No action has been or will be taken in Germany that would permit a public offering of the securities, or distribution of a prospectus or any other offering material relating to the securities. In particular, no securities
prospectus (<I>Wertpapierprospekt</I>) within the meaning of the German Securities Prospectus Act or any other applicable laws of Germany, has been or will be published within Germany, nor has this prospectus been filed with or approved by the
German Federal Financial Supervisory Authority (<I>Bundesanstalt f&uuml;r Finanzdienstleistungsaufsicht</I>) for publication within Germany. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each manager will represent, agree and undertake, (i)&nbsp;that it has not offered, sold or
delivered and will not offer, sell or deliver the securities within Germany other than in accordance with the German Securities Prospectus Act (<I>Wertpapierprospektgesetz</I>) and any other applicable laws in Germany governing the issue, sale and
offering of securities, and (ii)&nbsp;that it will distribute in Germany any offering material relating to the securities only under circumstances that will result in compliance with the applicable rules and regulations of Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is strictly for use of the person who has received it. It may not be forwarded to other persons or published in Germany. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Arab Emirates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates
(&#147;U.A.E.&#148;) other than in compliance with the laws of the U.A.E. Prospective investors in the Dubai International Financial Centre should have regard to the specific notice to prospective investors in the Dubai International Financial
Centre set out above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in this prospectus supplement and the accompanying prospectus does not constitute a
public offer of securities in the U.A.E. in accordance with the Commercial Companies Law (Federal Law No.&nbsp;8 of 1984 of the U.A.E., as amended) or otherwise and is not intended to be a public offer. This prospectus supplement and the
accompanying prospectus have not been approved by or filed with the Central Bank of the United Arab Emirates, the Emirates Securities and Commodities Authority or the Dubai Financial Services Authority, or DFSA. If you do not understand the contents
of this prospectus supplement or the accompanying prospectus, you should consult an authorized financial adviser. This prospectus supplement and the accompanying prospectus are provided for the benefit of the recipient only, and should not be
delivered to, or relied on by, any other person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document relates to an exempt offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority. This
document is intended for distribution only to persons of a type specified in those rules. It must not be delivered to, or relied on by, any other person. The Dubai Financial Services Authority has no responsibility for reviewing or verifying any
documents in connection with exempt offers. The Dubai Financial Services Authority has not approved this document nor taken steps to verify the information set out in it, and has no responsibility for it. The notes which are the subject of the
offering contemplated by this offering memorandum may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the notes offered should conduct their own due diligence on the notes. If you do not understand the contents
of this document you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Kingdom of Saudi Arabia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities
Regulations issued by the Capital Market Authority of Saudi Arabia (the &#147;Capital Market Authority&#148;). The Capital Market Authority does not make any representations as to the accuracy or completeness of this prospectus, and expressly
disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this prospectus. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the
information relating to the securities. If a prospective purchaser does not understand the contents of this prospectus he or she should consult an authorised financial adviser. By accepting this prospectus and other information relating to the
offering of the securities in the Kingdom of Saudi Arabia, each recipient represents that he is a &#147;sophisticated investor&#148;, as set out in the prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Israel </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, and has not been filed with or approved by the
Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust
funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters purchasing for their own account, venture capital funds, entities with equity in excess of NIS
50&nbsp;million and qualified individuals, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors. Qualified investors may be required to submit written confirmation that they meet
the criteria for one of the categories of investors set forth in the prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in South Africa </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to restrictions under the securities laws of South Africa, the securities are not offered, and the offer of our securities shall not be
transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the offer, transfer, sale, renunciation or delivery is to duly registered banks, mutual banks, financial services provider, financial institution, the Public Investment Corporation (in each case registered as such in
South Africa), a person who deals with securities in their ordinary course of business, or a wholly owned subsidiary of a bank, mutual bank, authorized services provider or financial institution, acting as agent in the capacity of an authorized
portfolio manager for a pension fund (duly registered in South Africa), or as manager for a collective investment scheme(registered in South Africa); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than R1,000,000. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not, nor is it intended to, constitute an &#147;offer to the public&#148; (as that term is defined in the South African
Companies Act, 2008 (the &#147;SA Companies Act&#148;) and does not, nor is it intended to, constitute a prospectus prepared and registered under the SA Companies Act. This document is not an &#147;offer to the public&#148; and must not be acted on
or relied on by persons who do not fall within Section&nbsp;96(1)(a) of the SA Companies Act (such persons being referred to as &#147;relevant persons&#148;). Any investment or investment activity to which this document relates is available only to
relevant persons and will be engaged in only with relevant persons. A South African resident person or company or any <FONT STYLE="white-space:nowrap">non-South</FONT> African company which is a subsidiary of a South African company is not permitted
to acquire the securities unless such person has obtained exchange control approval to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;to &#147;professional investors&#148; as
defined in the Securities and Futures Ordinance (Cap.571) of Hong Kong and any rules made under that Ordinance, or (ii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies
Ordinance (Cap.32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the depositary securities may be issued or may be in the possession of any
person for the purpose of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong)
other than with respect to depositary securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under
that Ordinance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus supplement and
any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation
for subscription or purchase, whether directly or indirectly, to persons in Singapore other than </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in
Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities
pursuant to an offer made under Section&nbsp;275 of the SFA except: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to
any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Residents of Malaysia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
securities may not be offered for subscription or purchase and no invitation to subscribe for or purchase such Certificates in Malaysia may be made, directly or indirectly, and this prospectus or any document or other materials in connection
therewith may not be distributed in Malaysia other than to persons falling within the categories specified under Schedule 6 or Section&nbsp;229(l)(b), Schedule 7 or Section&nbsp;230(l)(b) and Schedule 8 or Section&nbsp;257(3) of the Capital Market
and Services Act, 2007 of Malaysia. The Securities Commission of Malaysia shall not be liable for any <FONT STYLE="white-space:nowrap">non-disclosure</FONT> on the part of the Issuer and assumes no responsibility for the correctness of any
statements made or opinions or reports expressed in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in China </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a public offer of the securities offered by this prospectus, whether by sale or subscription, in the
People&#146;s Republic of China, or the PRC. The securities are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the securities without obtaining all prior
PRC&#146;s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Korea </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the
decrees and regulations thereunder, or the FSCMA, and the securities have been and will be offered in Korea as a private placement under the FSCMA. None of the securities may be offered, sold or delivered directly or indirectly, or offered or sold
to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign
Exchange Transaction Law of Korea and the decrees and regulations thereunder, or the FETL. The securities have not been listed on any of securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the
purchaser of the securities shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the securities. By the purchase of the securities, the relevant holder
thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the securities pursuant to the applicable laws and regulations of Korea. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Taiwan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities
laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or
approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the securities in Taiwan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus supplement does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations
Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the securities may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the securities without disclosure to investors under Chapter 6D of the Corporations Act. The securities applied for by Exempt Investors in Australia must not be offered for sale in Australia
in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the
Corporations Act or otherwise or where </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring securities must observe such Australian
<FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. This prospectus supplement contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It
does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus supplement is appropriate to their needs, objectives and
circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Cayman Islands </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute an invitation or offer to the public in the Cayman Islands of the securities, whether by way of sale or
subscription. The underwriters have not offered or sold, and will not offer or sell, directly or indirectly, any securities in the Cayman Islands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Bermuda </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business
Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such
persons are permitted to do so under applicable Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the British Virgin Islands </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription
by us or on our behalf. The securities may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (each a BVI Company), but only where the offer will be made to, and received by, the relevant BVI
Company entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been, and will not be, registered with the Financial
Services Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of the securities for the purposes of the Securities and Investment Business Act, 2010, or SIBA or the Public Issuers Code of the
British Virgin Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be offered to persons located in the British Virgin Islands who are &#147;qualified
investors&#148; for the purposes of SIBA. Qualified investors include (i)&nbsp;certain entities which are regulated by the Financial Services Commission in the British Virgin Islands, including banks, insurance companies, licensees under SIBA and
public, professional and private mutual funds; (ii)&nbsp;a company, any securities of which are listed on a recognised exchange; and (iii)&nbsp;persons defined as &#147;professional investors&#148; under SIBA, which is any person (a)&nbsp;whose
ordinary business involves, whether for that person&#146;s own account or the account of others, the acquisition or disposal of property of the same kind as the property, or a substantial part of our property; or (b)&nbsp;who has signed a
declaration that he, whether individually or jointly with his spouse, has net worth in excess of US$1,000,000 and that he consents to being treated as a professional investor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_15"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Fenwick&nbsp;&amp; West LLP, San
Francisco, California. Certain legal matters relating to the offering will be passed upon for the underwriters by Cooley LLP, San Diego, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_16"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of AnaptysBio, Inc. as of December&nbsp;31, 2015 and 2016, and for each of the years in the three-year
period ended December&nbsp;31, 2016, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, an independent registered public accounting firm, incorporated by reference herein, and upon
the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_17"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect
to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits filed therewith. For further
information about us and the common stock offered hereby, reference is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is
filed as an exhibit to the registration statement are not necessarily complete, and in each instance we refer you to the copy of such contract or other document filed as an exhibit to the registration statement. A copy of the registration statement
and the exhibits filed therewith may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from
that office. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information about the public reference room. The SEC also
maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the website is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the information and reporting requirements of the Exchange Act, and, in accordance with this law, file periodic reports and
other information with the SEC. These periodic reports and other information are available for inspection and copying at the SEC&#146;s public reference facilities and the website of the SEC referred to above. We also maintain a website at
www.anaptysbio.com. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the
inclusion of our website address in this prospectus is an inactive textual reference only. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc453477_18"></A>INCORPORATION OF
CERTAIN INFORMATION BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we
file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes
information incorporated by reference that we filed with the SEC prior to the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into
this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission <FONT STYLE="white-space:nowrap">File&nbsp;No.&nbsp;001-37985).</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2016, filed with the SEC on March&nbsp;8, 2017; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Reports <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-Q&nbsp;for</FONT> the quarters ended March&nbsp;31, 2017 and June&nbsp;30, 2017, filed with the SEC on May&nbsp;12, 2017 and August&nbsp;10,
2017, respectively; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on March&nbsp;2, 2017, July&nbsp;27, 2017, August&nbsp;24, 2017 and October 10, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference, including
exhibits to these documents. You should direct any requests for documents to 10421 Pacific Center Court, Suite 200 San Diego, CA 92121, telephone (858) <FONT STYLE="white-space:nowrap">362-6295.&nbsp;Copies</FONT> of the above reports may also be
accessed from our website at www.anaptysbio.com. We do not incorporate the information from our website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our
website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified,
superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">3,000,000 Shares </P>
<P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g453477g71b77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Credit Suisse </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Stifel </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Wedbush PacGrow </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Baird </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>SunTrust Robinson Humphrey </B></P>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">October&nbsp;12, 2017 </P> <P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g453477g04v98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g453477g04v98.jpg
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M 0$! 0$! ?_  !$( 4("70,!$0 "$0$#$0'_Q  >  $  04! 0$!
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M7)R[83"MYMYBNCX'G1Q11:)BOC==E55W0LU*KA6U-EE=2UNEE#W[S8+6KK5
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MVC-HZ!MXT)"GJUC_ $![4"J;&UEU^/["H9BL;'[&@-HW:@4H<9HL2&>KE)V
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M:$J(N&FP*/.?F.Y&KLVIUWYYV9QXXB.(CB(XB.(D%[OZ^4;L%7K#5-A2[&X
ML.N-@ZV<'B"48>V+B;*$)K]@M(E2Q\E;-R8 YEA Y:4J9%'B"Y\;Z<]#/F&9
MM/,P:LU'KN:S8]%U&B,%VB]0CV+U'XP)JBL=0%=UTT=@;>)FW83I90$#I?3?
MJRD[C0V]*VZQK47T9E&A+*C;@44C+-6ZS$ZIJT:L"R98WEML6W*,FT!V)\W
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MZZBZ-:I6U-\ 9V@8&^!-..Q+'0VCDX1V'./6>\CC<UC6["$XAV!]TE7"%?8
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M:@T&U%]+$ZLS$Z/F7,P-9Z,JA@E6.UB(@=R[@:NSG<QU.YV.@500J*JP-,Z
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M>9Z,G(7;;9IIIHR]6S^5=3M .FEMN,9;UM4W)*/ATX##EZ'HN.=U5>H8'52
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M1/6)H@7E@30P96O*RX,"4 Y/$<_(Q,S)&6,JO M:A,3B.)87JPV"(ME>72I
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M'Z>Z4_>3>G\O?'EY?\WU=\_@CR*H[?;W"?J1^7+VC'Z>Z4_>3>G\O?'EY?\
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M!QPYRITS7_6VP")!"'AW$L\Y.V3I2[6!! KEQ"I<5DPV)8RPC$ ?$PIW#CV
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M%:M=;AUL=>L$X;OJ.2B[6.>H16+-:6RM-":\EY7-C#V8 U?R-7 U994)&0?
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M$<1'$3BW[7W_  \_ZL_\9\DK]?L]\397IGV6F6S6O7/7"^N'9VK,NZBH(O\
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MB(XB.(CB(XB.(CB(XB8?<M>T+8L03 V!2:E>8($Y"LX.';ZX(LD8-9!S,J-
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MO6YOC^YK'5Z_ZZ>XQ%VUSVK+A*'#HW9RATLZ%K^(.P#93K@S<(M[L>,1L9L
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M.(CB(XB.(CB(XB.(G/\ V0<N%=[:;5G4MXP3.C^A)RT5>LND2A$-(NPS89Q
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MB<O]5[S7?^]==41A;P"*M?7'8[(BE7/2&^*'7:>T,V-1B Y$]^Y:_K]79+S
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M$1Q$<1'$1Q$<1.+?M??\//\ JS_QGR2OU^SWQ-ENFG8&_676G7.@DNH_8ZE
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MK>CMC$IC7R19?/RXV55U,+S$QA$0>PFP)>LC6P'>H?9(>?%66*!BZDF/]?\
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M6!MU4P-\G6BVIQ%8=]64+D^%'<1!3L)L ?K:LWR/U"[)%SI\R2%3]4C7^O\
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MW\]6I'U_AZ/RB;,3NYNP'1FUW*GK !<SM#TM^.P(57+"3)P+-7!>QKI4+-6
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M6#76JG\F; V=<9(PZD%9_0CYZMZT(TNOG/ETP\%,6>&6@P72,*'[GR_W_?\
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GXB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g453477g14h75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g453477g14h75.jpg
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M*#1ALT)W@9&V_\0 ' $!  (# 0$!              $" P8'!00(_\0 6A$
M 0,! P,+#@L%!@0' 0$  0 "$0,$$B$%$S$&%1<B05%3DY31TP<4%C)456%Q
M@9&2TM3P(S5"4E9TH;&SP=4S-'65M%=B<Z+A\4-C<K(D18*#A,3BPB7_V@ ,
M P$  A$#$0 _ ._G@UX/.$<_P@<*9T[PL\.1HX:X;=&%C)DMI#69(J6*DM81
M=X1)DR+R,+.WY!^[66=/7KI95RZ<JJ+KJ9JYY97V:C1HFC2)I4R33IDDTVDD
MEHDDPO!K5JPK50*M0 5*@ %1P  <8 $JR7B2\&7Q1N&+V":J^JE9<Q0X&EQ;
M.98L_7X:KQC^=/$EX,OBC<,7L$U5]5*9BAP-+BV<R9^OPU7C'\Z>)+P9?%&X
M8O8)JKZJ4S%#@:7%LYDS]?AJO&/YT\27@R^*-PQ>P357U4IF*' TN+9S)GZ_
M#5>,?SIXDO!E\4;AB]@FJOJI3,4.!I<6SF3/U^&J\8_G3Q)>#+XHW#%[!-5?
M52F8H<#2XMG,F?K\-5XQ_.GB2\&7Q1N&+V":J^JE,Q0X&EQ;.9,_7X:KQC^=
M/$EX,OBC<,7L$U5]5*9BAP-+BV<R9^OPU7C'\Z>)+P9?%&X8O8)JKZJ4S%#@
M:7%LYDS]?AJO&/YT\27@R^*-PQ>P357U4IF*' TN+9S)GZ_#5>,?SIXDO!E\
M4;AB]@FJOJI3,4.!I<6SF3/U^&J\8_G3Q)>#+XHW#%[!-5?52F8H<#2XMG,F
M?K\-5XQ_.GB2\&7Q1N&+V":J^JE,Q0X&EQ;.9,_7X:KQC^=/$EX,OBC<,7L$
MU5]5*9BAP-+BV<R9^OPU7C'\Z>)+P9?%&X8O8)JKZJ4S%#@:7%LYDS]?AJO&
M/YT\27@R^*-PQ>P357U4IF*' TN+9S)GZ_#5>,?SIXDO!E\4;AB]@FJOJI3,
M4.!I<6SF3/U^&J\8_G3Q)>#+XHW#%[!-5?52F8H<#2XMG,F?K\-5XQ_.GB2\
M&7Q1N&+V":J^JE,Q0X&EQ;.9,_7X:KQC^=/$EX,OBC<,7L$U5]5*9BAP-+BV
M<R9^OPU7C'\Z>)+P9?%&X8O8)JKZJ4S%#@:7%LYDS]?AJO&/YT\27@R^*-PQ
M>P357U4IF*' TN+9S)GZ_#5>,?SIXDO!E\4;AB]@FJOJI3,4.!I<6SF3/U^&
MJ\8_G3Q)>#+XHW#%[!-5?52F8H<#2XMG,F?K\-5XQ_.GB2\&7Q1N&+V":J^J
ME,Q0X&EQ;.9,_7X:KQC^=/$EX,OBC<,7L$U5]5*9BAP-+BV<R9^OPU7C'\Z>
M)+P9?%&X8O8)JKZJ4S%#@:7%LYDS]?AJO&/YT\27@R^*-PQ>P357U4IF*' T
MN+9S)GZ_#5>,?SIXDO!E\4;AB]@FJOJI3,4.!I<6SF3/U^&J\8_G3Q)>#+XH
MW#%[!-5?52F8H<#2XMG,F?K\-5XQ_.GB2\&7Q1N&+V":J^JE,Q0X&EQ;.9,_
M7X:KQC^=/$EX,OBC<,7L$U5]5*9BAP-+BV<R9^OPU7C'\Z>)+P9?%&X8O8)J
MKZJ4S%#@:7%LYDS]?AJO&/YU3/;;SW-/26P=CP.?\%NH1[74D"U-L_8L\:<-
MVB'T*C$$W'.I%KJ-2)W=*UI:Y9BY+%BV$IQ'Q)XX"BT\3-T7(RR[E#"_K:FY
MS74&"ZUCW.S5,M#7N+ ?G=L#,-D:="SL%JJ,:YM=^W<]C&YVI><YC0X@?)T$
M1+A.C2II4U9[ENDNDU4UAP'8.5RT@ MV^4!T%BNX-10$2D\G$MTKA^D<$(]&
MPQB0&6B..:PT*)*%'>"3(>[61O<LNBY9YDCM:>D DC1I !)&X 2< L=^U_.M
M&@'34T$@ Z=!) &^2 %IDLCON7D1E&OXNXX?>$<Q>>SB:Z_6/@=1Z ?1J '(
M!K/9NU9*OLDFLT:9Q84RCNH9VR5(7;/<&AX,Y&D\&&+4@Y95(LH+1FZ)O.<V
M0RF0TM:YYO'Y.#'>4085@;40XYRL+K6N@OJ N#G-8+HW<7M\AD3@MDS@7N4B
M1,:%5U_P!HF2^=DQ@A:$\/R)5ZID>)Q6R2 Y43@\S5\*@I:+W2Z&REI*.> +
MXV+H*,[6NV20+MGDZ!%*3!@QY1'CPTJ+UK@F]:(&DS4@8 Z9WB'>+'1BL<'C
M7N1DAMS@,5]SO,X=Z7A[I!<:X<GR5P@^+#IP^,65;,%$[C&L++#98L^ME=KA
M&WB)NZO>Z]W-H L9T"S'=P%+1%Z?%=,SO8H3;!I-I&,8FKIF['CG"-_#2ON8
MAWN3@!?)F8@' .Q(XA<Y#80I M"YG%0J8^8%;D&P-(*H7=(YL-?3M9'%LR55
M7RALG0034< R23<6V0:6V<&)B[3F,= B3VKM'S3O% ;8=#K0<;LWJD3M1$S
M[9N[\IN^%HDU2]S&A@721GQ5.'60^,7$3DPTP.%Z)T$&>SQ(&"CL@M&@JT[3
MAPEQ.C;*4#,(W",2=Y*<<)E<&0[-,*56:0X65MSX&F<X"6 4Z8+H ,"]=!<9
M$-F2?$8LWKIQJ#/5!FG!KYJ5#=DD2;MXW1!ET0,,9(G>0$*]RMDA D*'ZCX*
M4"0S8<EU4HP,:CTT"?.YW$#[")R$$-9&(VR=D%6,L*,(PFNV1S;$#KUBP&JO
M%" [NN0VRDD!E"0\L[1G;-(:0,,=L0WPD@#2)J76L0;]<@M#\'O.U()!,$Q@
M"<=P8K*A-;>Y7258<VCNM^ <ZY+/QHL8W$0;A_(N'Q RE$EPK5L@T$JJJJ&T
M)_ 5@O-POB72GD)4'9.<)='KD9#;(=#;.9P$-IZ=K&YNWFQOWFQVPF"ZUB27
M6@ 23)J# 3.D[EUT[UUV\8U#:44]S@U#N'6^D99PB:"M+MF1V0R\6\:</>DD
M8X%B43?#F,GDLA*F& C-$3';%&Q(^J(:&5@0+!R?,(,0[95[C5XLS'M8ZC3E
MP+IS=. UL223& F3 ,"28 )5F&TO8ZHVM4AA (-1\EQT  3B= F). Q6[;<T
MY[G7I%GKTCL#A<X:1X_9NS81J6,OFG#UJQZT\*]AD<0\7S*N4XOBB+"/"RK(
M8H:<YXLD7Y,6TRSNN1:IJ6>RS,#2ZE2ASFL$4V'%Q@3A@)@3X0JL?::EZ[5J
MFXQSS\(_M6B3&.)C&-X$[BU;84>]R;U<C/\ PRUGP.,"NKQ9DM.8JUU=I(I-
M0#<"RC! F@[APV/.I'B_;LYM#7%V-QMG/02R.N+IXMS#%5:KA9&7KS: +02X
M7&%PB/D@3\IN$;HWU9IMCRVZZT&_@TWJ@:9)&#B8TM<-.X=XK$YA_<O&T;E\
MB)</O!R'SBIO:()J"*0?A2;F9<YU,J01D2T;RQ*JA4$7*@U;!HC+#,7(BU,T
MT9>QBZ]ETD464 DTZ(B_@11DW)!C&-S=((^5=3_Q<M J5C>##(-8AH?!$X3N
M[@(/R25L "'^Y42!-NDAJ[@0:F\F(UV_BB\*X<'<E"NB?@8DD&), K8LCD93
M?;%@8O)H-=D4W)&9Q- <N^QDP)0C(;9#\BSSO12)':X0)^<W1/;-C2)@FU@]
MM:-V#-4 Q.()C#:N/B!G05PQD?\ <FC!4^*8:UX&U?!L=#"A MGJ_22$<69S
M^*')Y&%1$C7CZ88XF\@L=+31=<.]>MF,6:K''BZ+!L\6;(LA)%VAA=)-QD;8
M%P@Q!VH+L-#<3@I)M@ )=7Q+@!??,M<&F1,C;$-QB78#%<N.:_\ <WIENZ5:
M#A_"WPQRN:PV".9T?>1W26ABT<8V830E "L0<D&C-1VPFX:3"G;(N$*#F"([
M/')%R_P>(/&K8&V8O--M*D7-;>,,ID#;%I:=YP(Q!&"@NM+:8J&K5#2ZZ)J5
M 3+;P($]J1H,_9!4 B=C^Y<&85IB9M>"O5:&6ZMQS/18^+$N&WA]%R>!SV -
M)>0DZ&S,'[IN!C8QF-ACXHV(,CYFQ(22"%1R+D<^S=-\8=92UCA09MWNIAII
M4P6N:"77I@" )TG @[JREEK#JC<^_P"#8*A(JU"'-=$7<))DQH&((W%(^F/W
M+S="!#)EPR<+L%>LCNOHXS&3[4W#.V6DI79>I]-;?C2<.)1-Y+H]+FB@+?.N
M *A./FB QU+S38.&=E4"8 @9NP65_P#PJ33+1#F4L;S&/%TMO!V%1HEI(DP)
MD$T?UTR#G:K@0YVU?5P#'O8;P,%N--Y@B;HDQ!C<DHO[E&XEC:%M=5<$KLRZ
MA;&?I*-=2Z97$7BYF0Q^+1MYB<3C>0E9Q+#DG",HF/;NUG\BN09*BF[E)^/S
M=S=LDW;E"8![1D02 ,8C$D0)DR(D%1-KNWKU<"\6XO>#(!+L)G:AIO'0(,Z"
MLAA"/<G%'^0M.$^Y\9D< .4IS981/AUR<X1K&*I3OP@R2L.OEB&RA"R<PP)7
MM9FI%[W/IK9"L,W>,W;(3 ;9R8F(I3$7I\5W;3HC'0HO6O3>M.F[IJZ9NQX[
MVUC3.&E;S&^'KW.:8D[!(GH;@QDIBX]4KWJ!:GTH4(XCV[A-HY=*,V4>6<)I
MM'2R+9YTB>.31PN@BYQ2462QSD4[,XP*= F)@,83&B8B=.'C534M+1+GUVC1
M)=4 QQ&D[HQ6_>)+P9?%&X8O8)JKZJ5;,4.!I<6SF5<_7X:KQC^=/$EX,OBC
M<,7L$U5]5*9BAP-+BV<R9^OPU7C'\Z>)+P9?%&X8O8)JKZJ4S%#@:7%LYDS]
M?AJO&/YT\27@R^*-PQ>P357U4IF*' TN+9S)GZ_#5>,?SIXDO!E\4;AB]@FJ
MOJI3,4.!I<6SF3/U^&J\8_G3Q)>#+XHW#%[!-5?52F8H<#2XMG,F?K\-5XQ_
M.GB2\&7Q1N&+V":J^JE,Q0X&EQ;.9,_7X:KQC^=/$EX,OBC<,7L$U5]5*9BA
MP-+BV<R9^OPU7C'\Z>)+P9?%&X8O8)JKZJ4S%#@:7%LYDS]?AJO&/YT\27@R
M^*-PQ>P357U4IF*' TN+9S)GZ_#5>,?SIXDO!E\4;AB]@FJOJI3,4.!I<6SF
M3/U^&J\8_G3Q)>#+XHW#%[!-5?52F8H<#2XMG,F?K\-5XQ_.GB2\&7Q1N&+V
M":J^JE,Q0X&EQ;.9,_7X:KQC^=/$EX,OBC<,7L$U5]5*9BAP-+BV<R9^OPU7
MC'\Z>)+P9?%&X8O8)JKZJ4S%#@:7%LYDS]?AJO&/YT\27@R^*-PQ>P357U4I
MF*' TN+9S)GZ_#5>,?SIXDO!E\4;AB]@FJOJI3,4.!I<6SF3/U^&J\8_G3Q)
M>#+XHW#%[!-5?52F8H<#2XMG,F?K\-5XQ_.GB2\&7Q1N&+V":J^JE,Q0X&EQ
M;.9,_7X:KQC^=/$EX,OBC<,7L$U5]5*9BAP-+BV<R9^OPU7C'\Z\Y7W0!P^:
M$UAXI?5KI#4.O._G7QWZ\!M:PR)]]^]O4SWN[Z=X H_OAWO[X/\ N+NOI>Y>
M[7?0='W2MS_-RA3ILS-VFQLYR;K6B8N1,#<E>ED^I4?GKU1[HS<7G.,3?F).
M["]&' ]^!7P@_FNZ _5/$J]*A^PH_P"%3_[ O-K_ +>M_BU/^\JT595B2B*M
M#SB_X>A&SI=J.2[#&P^7P=T08R'.8).(S&6CL6!TS)7B'AB63;1>REA'$'IU
M1IBL51[YOILT#B^[3 PZP%X\]3#G,+@"W3. $!A[8X:*C-W&] D@QE%&H6AX
M:7!T1=Q.)J ;4;;32J;F :28!$R5?=>F[70M?;6LK7=$<@[6UYY%;7<EL'K,
M;F+0MWUY5B.)$B/89,D^<YQ>OF;6Z5EW**>=K[,-LW$P-L,3($#'3) \9"KF
MZGS'X"3M3@,3.C1 )GP%8QOQ"Z!>#DR[3>.GW0E9M9XB4;[,A:XY5I>1,(A9
MTF]2-Y-LVUY85%Q>R^*MTKR(DP"\[OD\;ME(SE.)SC(W[S8TANF?G$#QD#24
MS528S;YT1<=.B]HCYH)\0G0M[BDSA\\$V/0>61J9@\G"K3$S%#HN1";ND,4\
MUFUB(AT\9W<(XJI9*HV6Z1/%5.^>-K9XWO8.:X2TAPWP01YPJN:YIAS2TZ8<
M"#YBMEJ5"41*(E$55QG&;H1[)&D6(R,M$B#V?/-6H.9Q&S$/#VV&QA[:=KP]
MR9.MF8UD>\&GP]TDP>N&ZR[TBR"I8YFE\1]L0K4R8F#>N;8$;:[>NR< ;N,&
M-[2LQH5 ) #MK?VI#C=O7;P DQ(T^70I2<[WT>S?IBWFY=4M":JF220YSL.(
MH/U%<+Y8Y))LU3&+C-3'+#+'+#%.^5KXY6O:U[7Y+&HP&"]@.\7"?-*IFZA$
MBF\C?NNC'R+[M]W:7=N'#1IMW6#ITT4'I.VS>?119PU5+ME'@I-PBF6R414)
MM$5G0_!3'')ZV247;652PRRM-]FB^W#3MAA.(W=T!,W4^8_=^2[<T[FYNK6B
M'$SH-@Z$,$ML0<R0/68J"&4;D(R2.'J! WJP"@Y2L%<O4[(]U[LU6[OSU,5%
M \W!&FZ:PQW@ZJIJTQ OM).@ @[K!N?XC/(X'0IS52";C@!ID$: \[O^&_RM
M(TKD2OB*TU#1T(-EY['U8YL"9NX%'Y0))L2\73D0Z'RN?$TS4B8.5A $>+B$
M(E)LF7+.V@U@W$YHN72;MTQ;N9-1@#27"'&Z"#(D!SC)T  -)).\@I/)< TR
MUH<6D$.@N:T0-)ESF@ 8F9T25@)AQ9\/,*\'>^6THH3\*DI*N$M%B[&67=(Q
M(=,B)I=2T?</[M6B%]>S84F^=618JR*-%8WBY[^-[L+P:M,1MP9F(-[M9G1/
MS7#>D$:<%+:-5TPQV$3(([8M T_];3_TF]HQ6U2'B$T3%1A\P?W%K0>PBS4V
M\/Y932/KN1B,;!NY*=P68-7ZY#-V+C[!Z9=L$6JKY,<V6==SW2POE4FI3$R]
MHB9VPP@7CA,R )C3"J*=0D ,<2Z(VIQO&!CHQ) !T2OTQW[IAXS?/5=FP@0B
M.*2(2[Q/R<("736B\X-:X)NK(%'S93(9G,H^5!L">.-V1%XVNBT654O;"F<I
MQ-]N$@R0(AQ9N_WFD Z#N)FZGS'&8. )TM#QHW;I!(T@:5)H8T'D8<7(8\6&
MG@!P<R+A#@9^U*!S DDW3>#B@LDQ579$!S]HLDZ9/6BRS9TW53705S2SQRO8
M$$ @@@B01B"#H(.Z"JD$$@@@@P0<""-((W"%DJE0E$2B)1$HB41*(E$2B)1$
MHB41*(E$5,]K\#>H]T[&V/L"?')\1:[<@&IM7;$U^W)1EI!I-!=.3N1[%C8!
MUAA$LI>W:E9)*2UY5DQES54R*5Q#V4:C[K(+87T&5'.<XN-YK&.;(#2UCB\#
M 7L23.VQ&&"SLM#Z;&M:&BXY[VN@W@Y[0TG3=T 1+3!Q6)AGN?6@(7"8Y 6J
M$@*!8;M\%N2(O'^,182,(7CAJ1D1<8<R6+Q".FI=$, DPE4!=LYZ\E9HGK^0
MEXP2.NV[Y=7.&V>FUH:)AKP\3=D$$PV0T$MAQ;#KQNDB<5+K34<XN,2YA8X8
MD$.B2 20UTAK@6W0'-!A1L=]RLX:Y)#;Z_+$]AJ1*TJV_)4V#)?7@DGDUW/!
M=W:].Q4C+A6N&<TD4;C03B"V*K!O">1&C\>>NAW*>>L&B[!Y4V6F6W9==EY@
M70=NVHTB;MX@"HZ[))!W=Q6Z[JAUZ&WH8,;Y&T=3<#!? )--MZ  << M2?>Y
M@1,IOLY.2,VE"NMI.UC$VEC-(R$3FTPW?%>(=WQ "#1S#J]N!80L6>0BUV J
M)N(XY7RC#9@91*CR!FY*.M1G"Z\;IAQQ%YU05<X"=K%T&[$1H@SC-A:R*0;=
M;?%YK<#=;3=2S9 VTEQ$XNO:9$$"/RO[CYPSNXH*AKR;;R=!0L1C,/'8*2:!
MI.46</X<&/#!'"-W#76C?-0J.@@P>;MFI;)@ZF37%^]'N0:KB.K1UG2+0TNJ
M0 !I;\FD*0/:Z;H!WKV,1@G7M62X-IR7.<<':7535([;07$C_I,:<5)LI]S4
MT=,#R4A+RK9+9YWOUT/>LHVGJB( R/5MXPB@]XJ!BVJ1 D>]/O.)K9Q*4J@V
MHG D27$/6J0]9H]R)7-F83,N':2!< -S.1@& "<ZZ]$3A$8S1MJJ-P :<7&3
M?<=OFMTO)P%%@;,P 1BI#GW!#K#:&B85PY3Z1S26:OANK'.I\A1UKKDBXD([
MO9&0X*8DU%]>W:A]E0IA&K80B;0EG$R4<<&SK]KCD^<M'#&SJ#'TQ2<7%@9<
M@W#.  =BW!S0-JYL$23IT5;7>RHZJT-:YSP_"^(Q)+1MI+'$[9KB08&\HCF'
MN9.JI0<4D&&U=V-+-MMGMYA8@L5UL2@C'8IO=L*X@,W+D47U:3)DA:<\@[-C
MS"1A\6O#STHCMRN2)-%9I0V5I,WZG;FH&RRZ'&H*FBY/;-C23=)$XJXM;P +
ME/M!3+H>'%K:;J8$AX':N)P %X Q@M'X;?<QQ.K2>NI9LV:LY=,=6(LAT>=!
M8AKM5E( J4<T>(N-G5CVN,VQ/./.N'C4M]=2",!H?.($,A@\8(F-QRB X9%*
MS7+A<X.<R "&MQ$4QMI:08--EQS0US0T0[>M5M1>'-:VZU\S+G2#>J&6PZ1.
M=??!+FN+C+=^9-W>YY:OWGM<AN0ULW=44E[@IK>1AK1$SK]0;$)3K,>= #CD
M61F>MYB\9,Y3$Y.>B&QX.\?$-9[! $W24IA)%_GW?5GV=CWEY=4#B6$06P"P
M$ @.:[2'%KFS<<"9:296.G:7TV!@93<T!PVP=)#B#C=>W%K@',=@]I&#@,%+
MG$7PH:_XH8><A&S)#/$PQB#.X6W4C)<,%(1]V[/1Z2^'()WE'7ETYNR,Q.-/
MQ3TDF3!B'@5D_&1]J1Q4>*7J4FU6EKBZ"TMP(!$D&1AVTM!$R 1@%6E6=1(<
MP-D.O8@F<'-NG'M2'&8@F<2H V'[F/I;:!G8$BENQ]VNC>RUYR^DY!L9UPTS
M4+[ U!I;2YHPS03U?W*V>-XYH:#%QR%T%!B4DS..70]X(()!6>-]F8\N+G5)
M=>F"SY5.G3/R-ZFTCPSN&%D;:ZC T!M.&70T0[ -?4>!V\G&HX'&8C&1)S#'
MW.74XZ0[3E#39.Y<2^ZH]MV,[+56?:P=(2(9N&1&983R39NM5K- ;^*2"2R9
M]#24?1%O6N)]^R/K2(>B-:L)%F8"]P<^:@>'XMQ#R2?D8022V(TF9$1!M3R&
M"ZR&%A;@[ L  QOR9  <#(PD &2H8AWN6,=3,S5W-MJ;#9,V6T\);IA: R"+
MM2@".80?A9BCM>8W,:OS;%)9(\.&0>(DC/"Y"%.(E*SC >"8%G")9GC;9 "Z
M7N&VEETB0+M)IO2S$G- '2TM)$ XJ[K68%UC22V*EX.Q-ZJ=K#\ ,[(.#I Q
M(F=HC/N3'#M%6\1;,9EM@BWA:L-S&,I-?4$K#OD8AK.>:=S8GXY(M0$XX=&R
M;7&PS4=D3$D)<-N<U$F . ,ZU7).["R4Q&+C%WMKA&U8YF(+(,M>09&\1!Q4
M&V577B6LVU[1?!%Y[7X$/!!#F @S.D&085A-*\%NMM"[$D.QH1*]BJO#8'8D
M;81XX0B3Z.187LW=DOW_ "' #9O#&)]PLAL.<R-P+6DI^0W;"'2(MQB[3:-U
M<,C*#:;BYKG8AP -V '5'5#&U!.V<8O$X8;@6)]=U1H:X-P+22 Z7%C!3$[8
MCM0)N@8XK0W_ +G)HMT[%%&1_90(XQVM!-SE#08K#T7$HG6O=%$^'D(_.#7D
M'?1Y!%W S!-T=3C@4 N8D[O(TZ<WLBV:(UZV9((+@0]M0D$8N;3S0D%I&+29
M@"295NNJF((:06/9!!P:^IG" 0X.[8"))@"!NSI>M_<K.'G5\C@DJ!RC:!@K
M &@,4-M,;ZHE8\@"C^I>';3[ .2%%M4+#D[IAN%C3<D0D 9L(F J9 GQ<%(Q
M+0LZ&5#++386D.>;L 7KA$!E)D$%D:*+#(AT@D'&%9UKJN#FD- =,W;[2"7U
M7R"'@Z:U009:00"TQ*Y0'W+;A[BY8$5C\HVR*PC#^'%8X#9G(:C%X^3@&W(7
MN^(*QV-X0*PJ,B@VP84@21B,;;B(1F@?DK7.-<Q\SR'!9:8((+\+L"6P+KVU
M! NP!?;,"&XG#>&UU"""UF,R8=)O,=3=)+I)+7=L9=@,=,Z4_P#<>.%P@#SC
M:DIW6@%R:HIXLF\KA]NB(HZ1/Z*L<3<JZ_6>W)9@I(0E6:2CE01X9V;K8"\(
MPGE%E*]94HB]4B -+=QA9/:S.)=O7MR[M586ZL#,4R=\M.C."I$7HB6ANB;N
M[>VRM?K#@^U?J?::6XHT].X3/*$DX(6NQ'0"$Q^3#"I40>4?RF+ZP@T$ '33
M$Z/*F Q!\/4N&?3&8Y#TT$3-D6V9E%C'WQ-Z[=.#6@B0<0QK02""1.B\Z-*P
MOKO>RX0+MZ\,7N(,$8%[G$"" 1.(:V<1)M96584HB41*(E$2B)1$HB41*(E$
M2B)1%$4\W-&H)+HQKW(5)97/IA#]ASV/PZ),1[LP^B6KLXDUF!?',N5"#,<6
M9>>PD$S97(]\B963,$V+-9JW*.Q]'/#2&P2XM<X #&&1)Q(W7-&^21X8NUA<
MTND-:US&ESC@'/O71@"=#7$X0 T[L ZB4XNN&4-T=B.[]>H76S))H<T\W<=/
MD*1B3AY=#N;INFPNC/X$HS42YZ9+&<PVXW-WX4@N[X-:D/\ B-\X_NG_ /IO
MI-WPI%&J=#'>*,?E#1ITM=XKKIT&/RWXO>&%T^6&-]YZX5?(YJI7;X2)I?-5
M9-W+&&+=IER\Q\Y=OX'-V0ULRR77+/(C)&HQ-VN%(X-V=I3&<;.]>'A]5T;\
M&-"9FKIS;_1/@/W.:3O B=*^+SB^X;D APZPV["C[<$*P+KMP9X6[7=MG ]$
MB.LQ77=M1F>)1%X)38O7!!L+NN?CF+H@VP/B5'<&M2 )OM,"<'#1N1C&,B#,
M8C'$*<S5D L<"3&(/-N03OP#A@5D ?$_IZ3S>&:[C4D1D,JFC20NV[ *X%DL
M ?@TR=.WZ,@7:DE$VUU7 PZ&9.V%R0QR>C<C$V?X.@[S!.1587-:#)=,1C$3
M,[V@CQ@C<*@TGAKG$0&D R")F-&'A!.C @Z"H@UA[H3P[[408/!)$\ 'OR*
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M:E*O]F%7@9]F1VYM'56XYL]P*.4W+^>:5RUC?71!JKC>V; >%MIW7F*H-M?
M,3N#64),G2QHZJ2IFV2XQB]['NQ.+F7;I\EQN P,8Z2L@JO%R#VC'L;AH;4O
M7QY;[L=(G B!$'2#W/K33W8L7V/$G16"E TH-R0^V8M1$E0E:)W9(W;#N/+^
M&+(\D$"HSA$W(!M@C9J1"&3J9<"0%$(S$U@V-UG87!PEI!),0;TO#R-L# O2
M["()D00V,@M-0,+##@0 -(NPPTY%V)-V 9D$""""9S[O@&X<7I"$$EP<KR<Z
MYANL(%#L,IW*%&@:-Z?E^LIY!FB#%8@HSR48RS3NNS!!;-#+(TX JV*V=IFY
M!@4DV>D8VIVK6-&V=@&.:YHT[A8T^&,9DS M%4!PD;9SG.VK<2]KFNQC>>X#
M>G#0(F_2.BM=</4-\ ]8#'PJ-]TCG5FA L_,KXJ"HK&X6PM9X167<WP1CT3"
M-+VR4RNJHV4=+9*.7*ZN=Z=-M-MU@@8;I.@!HT^!H"QU*CJCKSS)QW -)+CH
M\+B5,-75$HB41*(JIRS@QT3-LC64B#'GG?\ VG(-RD<4Y,5:XYSV30\= BI%
M+N99/)%GG%A3 <@+PRLP0S0N^P0[O57<J8C1INF0<7EYQ(VQ;=.[HNX1HW=*
MS-KU&Q!&#!3&U':AUZ-&^9)T[FA8L7P+<.@,,6CX2-'0XDT&"1YZV%R^0L%<
MP<;G0_8 ,7=\U?)$56C$F*'AE,'+MQD4B+;&*F<B(919LK H4FB "! &!(P:
MZ\!IG X>%N!D*3::I()<"021+0<2TL)B(Q!)\#C>$%1U!O<U^'.(E4"Y$86E
M3J-RD2;UM<H5*XV@(4/KP-K).,MT\B3EM($"\4&+C9&1-MUW!9%_?/!)D]9M
MGUJMLU-IF"8<"V2=J T-C29D#$G3.^)5G6JJ9@@7@0^ -L2XNG1(@D$0<"/#
M"VL)[GOPQ1W!DF)BTD;X#UV2S7!2=2MUABF,SX;[BV2B;LFLFNQ'(\)>AFK9
MLOBIAT$+SNM=9<](5B<BST0(#=$:7.W,U TZ/@:>']WPF:FT53,N$F9-UHTY
MV3HTG/5-&_X!&XR#@UT;)M0Z]T87$R)QKC5J;EM"17A8;[N%,%]:RW3R(Y4W
MFYS+D6C#6DWD,497(O'3G%!R@5<.'!]FU+)6-&F6-ID$M;@!)T77,B9F+CBW
M?W>VQ516J->ZH" Y\%Q@8D/:^8T"7M#C  PC02%HSKW.WA>>7?W6BTDM<K>6
M*$[)3>3)8/G$U+;K-'W:Z*;_ !1[I6>\0^W.YE$T\+,F\H2;-L4T0,=P$UZW
MI8[4XWIASL;QJ$[N_5?XIPB!%A::H@!PPB-JW<S<#1H^"9ITQX3/(D'N?/#1
M)Q8 &: S!V%BL>F,4C0GK$F6# %'IO"]B:[+#1R&)>UDL6\)VC+(V,=9W4?-
M!N01/)TMG&P6;"39Z1 !!(:' "\Z '-<TB)^:]S1N@1O" M-4$D%H)+7.-QN
M):6N!.&^T$^7?,\U_P  G#,4+/#KZ(&'!A_*7$V<$%);(;N,I6XV-/\ :5SG
M+=_S.[$Y7M38>:=LL,D+BY2Z$*HJL1X1(6-GI$S=QF],G3><Z<3IE[_2(WH"
MTU@ +V  ;$#M0UK(T:+K&^43I)5F=<P"-:J@,.UI#&KAE$H'&Q$3C3)T\<$'
M#,&"9(CQC59\[S4=/,V[-!)&[ETHJX6YG2+JJ*Y99Y9&M#&M:T0UH  TX# :
M5B<XO<YSC+G$N)\),E;I5E5*(OY>][6O>UKY7M:][8VY.7*]K?>MSKXX\M_O
M6YV5K<OW[VM[]$5?X?Q-:IF24>41+*QY641.&3T,UEV8J/N'D+V&%DIR&2)K
MW45R0((FVT0D;?O6+7?2 2Z%KV/!Q3>Z3G/&VHUT8Q(:X X2UP):?#-TX#$1
MB LCJ3VSA,%S26R8+2 X'#"+PQ.!G E2 \VSJP?FHF_V1!&2B6+=17!U+ 3?
M)-)X0Q$-%5+*O\.8BZ+Y8"&ZN7(FL6SP&)Y9/L\4+VO-^<WTAOQO[^'CP5;C
MSH:X_P#I.].]O8^+%8LEO728;'',OM_6(O!1JX?)YD)W&&>*C-IDE@[=)9."
MB=E&[3)="SI;"^2;?IT+K98663OE!J,&E[!NXN T:=U3FZAT,>=SM7<RD8:4
M&&6:9 009%&"JBZ23T<Z0>-%%&KA5JY33<-\U$<\V[I%9LOCCG>Z2Z2B.=L5
M,,L;7F=&*I$:<%SZ(E$2B+3]@S@)K2#RO8,ENZQCT, DI(<S9))KNDA0EMF\
M?K(HK+MTU<D&R2BW1W6POECA>V%[YWQQO#G!K2XZ&@D^("3]BLUI>YK1I<0!
M.B2H_BO$EHR7-\<QVT(2T?XDC89V!+R<$-/L"\;[XY&V#D8L1Z7.[1J*>ED'
MS/)V*+1[%O* A E&R \LZJ*C#H<W21!(F1,C3X"<,",02,59U*HW2QT8&;IB
M#$&8W9&!Q!P(!P7UMQ#Z>3<'\2,\BX(;'%<<'\A/R:,AP"R2T?@$F9OAK]Z9
M2N2%OA.RXHHW*LT51]G3V[!RY;O<VB#IG&8RYH TDD 8AI!!)Q!#VXZ),*,V
M_"&N).( !)TN;B ,#+'8:</&MA2W#K"[=5P[GT-&V04.8K)OI;&;9I)1PHH)
M,.E,VQ9RA@W8.<$[OLLEK*#,'"&!9-@YNHW3F\WYS=WY0W#!.G<W=[=A1<?H
MNN.C0T_*$C<W=S?W)"V:)RD7,PN!X-W3W%D2/";XNT;(+IOHT>)QHLEFG;-3
M'FHE1+U)-3!3--9+#!9/*^"F-ZD$'$;Y'E!(/VA0X%I@Z<#YP"/L*V2I4)1$
MHB415HD/%MI6);-<ZIE4@5CDA9FB8-V0,8,F4;9N NO8MLXJ\)&E7]D@XEG%
MIK&5+%3"0]B](D5!@U9ZZ&%\6&(UJ;77'&#)$G1(:'F3N0UP,F!CAH*RBC4+
M \"00# DG%Y8,(Q-YIP$P,3$B98OM;6%D2#B^Q(1W.)206*+>%(3HAR3K%/-
MFH^S[MYK7!]@LBHPR7OA9\FJFHTZ;#/'*][S?G-\X5+C\-J['1M3C&F,,87W
M$["C1V7O88(<YD"#&$Q38-R+2[9R#=1J:DI,+CCL>30<J8/LGZ\1-*X]SIYH
M8M$6[CI[X.V_2 X$EHTAK7>"'$@8^&Z4+2!>(@7BWPRT D$;G;#W"WBK*J41
M*(E$2B)1$HB415YVAQ/:JT_+6\-G#XH/*.1<?+8+(,473.S63+S1$9?+FO,7
MM\<<=?RAR1=8,<QPAJR06*/6EG[*R^-]5C#=<<8!\]Z/#\ET[@C$B0LC*3WB
M6B<2/-=G_N$;IG &"I#8[<U44335&[)@;])9B-*)*LY:!<IJ###)4B))8J(O
M\\+CR;%!9VP>VOW*[0144054MAER6#VG0YIT' C=Q&[NC0JECAI:X:1B#N8'
M<W#I7R?[5B+5G%2X]RXD\>ELD;Q1I)8E@WD0$<6='4HHW3*O1[I2Z6%Y6NC'
M'5F:3Y<6_P"[7!=!@)#'20M?&!&()B6X@&8QC^]AX#I@ D+CI(T$"]!P)$7L
M)_N[;&)&B20#)%654HB41*(E$2B)1$HB415E0XNM(^'ZVMR<DRCL@2DY.(8K
M2'N :&5."R1X/=ID6R(J-F2Q(I'"+($S*78$3:MD,AC)RBK=3#%GJ=ZZ3!O%
MN. D2(GPP8!Q.]B%ES-2Y? D0#AI@@&8C$ $21(&Z5*N>W]3I#EC"NS("D);
MIK*N":LN ICVZ;9PZ:NLUWF;_%NCBT<L7J+RZBF/<BC1SBYZ+H%.;>^V";S8
M&DR(&G29\!\Q5+CYBZZ3H%TR9Q&$;Q!\JR:$Y"K3U[KGFO$Y"SC3>66Y^#;)
MHY#+O^]F2Z>2+I9XVZ)[?!!/,DS8-B:EGJ81P44"'\!4WA>N[L7O),>3RZ=R
M8,+INAVY-WQ'3[Q,;L2)W*I54HB41:'*M90F9GHS*3X=1630YL?81J1#"YN/
M'10R58#,9,&2+QXD+?K I!D#!.# )TX7$$7H$$_=LE7H48X:U+&N()&+9@@D
M$ Q(D$&# D:"0#I 5@YS00#@Z)! (,:#!!$B3!TP2-!*@MQP-\*3G-)3/3H5
M')O9?!"S(Q*QZ:*"^>M,^XTDF!]LDFP;8Z=UBW'#\,+,13*&B6 UNT98N&Z]
M#0I'Y'VN'S<,#HVC<-& 605ZH^6=S<:=%_'$:=N^3I-XDXK'7X!N$?)'N>^G
M6%TK9(J)\LJGEU&[AJ\VD28O6BWA3TS,B-)[JV@4%$FJB+\44EKLD.<MGK(2
MNPCK>CHN8;TNWWF=.D&H\@Z03AH$.N*WS_L;_<&]C(IL!&\(T$SO[SA8T0^P
M7P<PA3+-V\FKUX[3EDV;D7V6QXR(A\[:/RC>2)$7PF51^/@6ID&[=+!G;H*)
M+9L._ ]H_2MFJ9^3ODXNDW@&NDS)!  (T&!A(49ZKAMM%T#:MC:$N;A$2TDP
M=.)$PN%!.$CAZUI-[;(A.OK!IMCB0QP/92F:E%\,":DA5>8)MC$D(,$T\\I4
M>Q1PP:8X-$GV*#3%!%FQ3;0VC38Z^UL.QQDG3)W3_>/G1U:J]MUSI;O0W<C=
M G<'F4;E/<]N%AS'7<> 00I!L7:0U+(K#9M-11;#O:U[TW<6<J'W6&90A&+Y
M0TC(<T<I,I$\& AH:9X@8XJ'CK>E$!MW1H)&C#?TD8$Z8C' 186FM,EP=I[9
MK2,<=[0';8#M;V)!DSL,=X'N&Z.MQ_,A9(H:8IQ?GRPG,YE:4/7L.;P9J!*N
M"8TZ.L@3:H:VA26;@:@PLX1")H+IJ(/"*3L*%(?)QPQET[6[!D$8BXWS8[J@
MUZIG;0#>VH:V(<7$B(T;=V!W_ (Z$O=_H##M8Q?@HA4!C["+146XXG78\&,Q
M4P9-'!XUIZ0EU$<55%<\;OC14B05MS[XV7=*63QP3YN&/GY0:U@H-: T#.P!
MHQ+"?M)*]#)[G/-=SB7$YJ2=. >!]@ 7=]P4[=U.PX->$EB^V?KQF]9\,NAF
MCQF[FL;;NFCIOJN*(N&SENL3P50<(*X9I+(JX8J)*8Y89XXY8WM;[*-:B*-(
M&K3!%.F"#4:""&B01*^.M1K&M5(I5"#4J$$4W$$%Q@@PK-==&G?.QK3U[BW:
MM9<_0X:EQC.=8LQ7X&KQ;^9.NC3OG8UIZ]Q;M6F?H<-2XQG.F8K\#5XM_,G7
M1IWSL:T]>XMVK3/T.&I<8SG3,5^!J\6_F3KHT[YV-:>O<6[5IGZ'#4N,9SIF
M*_ U>+?S)UT:=\[&M/7N+=JTS]#AJ7&,YTS%?@:O%OYDZZ-.^=C6GKW%NU:9
M^APU+C&<Z9BOP-7BW\R==&G?.QK3U[BW:M,_0X:EQC.=,Q7X&KQ;^9.NC3OG
M8UIZ]Q;M6F?H<-2XQG.F8K\#5XM_,G71IWSL:T]>XMVK3/T.&I<8SG3,5^!J
M\6_F3KHT[YV-:>O<6[5IGZ'#4N,9SIF*_ U>+?S)UT:=\[&M/7N+=JTS]#AJ
M7&,YTS%?@:O%OYDZZ-.^=C6GKW%NU:9^APU+C&<Z9BOP-7BW\R==&G?.QK3U
M[BW:M,_0X:EQC.=,Q7X&KQ;^9.NC3OG8UIZ]Q;M6F?H<-2XQG.F8K\#5XM_,
MG71IWSL:T]>XMVK3/T.&I<8SG3,5^!J\6_F3KHT[YV-:>O<6[5IGZ'#4N,9S
MIF*_ U>+?S)UT:=\[&M/7N+=JTS]#AJ7&,YTS%?@:O%OYDZZ-.^=C6GKW%NU
M:9^APU+C&<Z9BOP-7BW\R==&G?.QK3U[BW:M,_0X:EQC.=,Q7X&KQ;^9.NC3
MOG8UIZ]Q;M6F?H<-2XQG.F8K\#5XM_,G71IWSL:T]>XMVK3/T.&I<8SG3,5^
M!J\6_F7\ON?3M[7M?;&M>2]KVOR3R,8W]_WO>RQ*VO:__*]KVO;[]KVO3/T.
M&I<8SG3,5^!J\6_F5?F<!X)F0D,#P/ZV=BP$?!Q(8T+[D=G<4XG&HO*(8#BK
MI0W-B"Q.,#HU-I>-1CQ-1X'S\)33Q9DJ_(.72F.]90 ,Y2@  35!P#2T R\R
M '.$&1B=TK)=M1).;J@DDF*1&)<'$X,$&\UID8X : %DQL;X/1.8O-G,8'EB
M$(N"@AN^W6^*LAKI[)8Y,W^+-@4G#QD@R)3&(QR6%!N"%AQ.2"T3;]JX)*.'
M"TW[-A\+2P,B:H,&0[==\YH=O2)TH6VHS\%4Q$&*,2+I;N,&AI+0=(!@8+B,
M(GPA1_N5Q$9MKF,D!*(G,!FSVUDL%%%8Z SC0 TI%E)KC'R9!B([G8/'#]BJ
MY.,F;-H8<O$VK:Z(/LPQ;5I"(B*H@0+H-V]&C X8@"4+;49O4JIF9FD9()DB
M;L@3B # W(4HP>;Z#U]#XS!XYM'6C8'%0H\&-3O.HITEVP]O@A99>^!/#'-T
MYRPR<NU;8XW6<JJJWMSL[U9M6@UH:*U*&@ ?",T#RJCJ5=SBXT:LN))^#?I/
MD6T]=&G?.QK3U[BW:M3GZ'#4N,9SJ,Q7X&KQ;^9.NC3OG8UIZ]Q;M6F?H<-2
MXQG.F8K\#5XM_,G71IWSL:T]>XMVK3/T.&I<8SG3,5^!J\6_F6LS.<</>P(I
M(81+=E:W*1B5"7@,\-3V4(&9/Q1!')N]:=WB) P)M<7".>:6:K)XW7MAEE;%
M7'EO4.K6=P+35I$$$$9QHD' Z'2I;2M#2'-I5009!S;CB/&V%&\CCG!_+#9R
M1FYI!E3,DQ*V-/6&[R(7)[D7CT-B[E7H0LZ'MF[AJ(U]$+!7+1%!Q'B0>QT
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M'\.&W0V.QF9WB/F#P9*LIQX*)"$R*2\4:3,NX)=['"DB.23N_$6I?NIL?%Y
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MRCI^'3;!L74@*"'KU1X/CG>DOH[J4DF]&W#QANW!3(..+2 3&&)&]CMK:H
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M8$3)DGL]K5EL*41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7DW^ZA?Y#G]9?\
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M^S),&CAD["O!)UBNY#F!;UV4P=[>^W0N)L3B1U=K"%#=@R8D]5BQ5[L%@S(
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M[! J12%\!WR0&W@<'7F3#@).%_2UN& O&%KQ29<;(TR]:1_4$3>QI=W,$F1
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M1?7:SAZ#$1P=DG)#3F,K.10M^J_=#@49V"^]C===%T:?@VU-TZ8=  Q,8 S
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M6QU:5=_7@RWIO'W.DMNG44\Q;[# -1(*4Z6+X,"3>'J-)E('X@0381X7WQ*
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M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7DW^ZA?Y#G]9?\
MR_T62GN^3\UZ$. #\ _@G_-'X;OU-PRBH=)\9^]97=YG?K&81975P%R2@@]B
M0%; :LU1MCAJ\Y#20:#-1)-^T2Z,CJN4!HF=-JJ'6#=[$Y1(&[(6?/LA3-(H
MPCP^_A_)55=-?= Q4JB37NLU(V@!-P/>R(?G!V8S9HYA+>&-V .R (\LT'P*
M7&->.^($#-$4!MXRG+A$@.QL.-0+:N;#2MA[SA@<//'O*D2+I<:2XAHVDY1P
M*++18QF0<W'1Y\.M,&^J-"N2S>R@ID\*L1[_ &TEO89#WP]%VT'L7Z1) 45
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M%>##4#T#K*+ET7I>/ZOUG.=9CA+ME&\6)Q"=D=>&GLPD#1$$FU=3<4=UG'I
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M>M7.#"(FI &?6*+E%2&(T&8Z027F\+L[>H*ITM,PX0V9AI(Q)E2+0\1H( :
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MC1/MVOAZ\M/#/\XYE]?6=#@1YG<Z=9'#!YS],^T:)]NTZ\M/#/\ ..9.LZ'
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M=$QSIDL;4;/<"$2+QK763PJB^<KB(M99W=1 L['8P:]"'@4!MI@D,ELTPT1
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M<ZG:K(2W-A[8+W"7 W=T;[J LNJ&UY0MS-3N4K/DRTML8=7JVFC3K-J4,_3
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MS?I*WZ(#=!S%H[=L==E6N#1QBVSQ=&2W.RRR3Q5YV/0R)2W-Y,K6]^]K\O\
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MFT[,1)JD$Q@"  #3ODXM)[>:4'$$!TD$!0:EH!(%,$ '$@F2'W0,"!BSX21
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M1$HB41*(E$2B)1$HB41*(E$2B)1$HB\F_P!U"_R'/ZR_^7^BR4]WR?FO0AP
M?@'\$_YH_#=^IN&45#I/C/WJW%%"41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB@7?T%DL\CX-A&6:3UTR,9/'&"KMJSM@A=DNC;*V;I5+#._2*8VYN-
M[Y<E^7DY+7O7-^J7J=RMJCR7D^S9)L[;16H6\UZK7UZ- -I=;U:=X.K/IM.V
M>T0"3C,0"NA]3G5!DO4]E*WVC*M=U"E7L(HTW,HUJY=4%>G4@MHL>X;5I,D
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M9 )-&C%X,/P(D.,0"+DB9!Q$009@@KF.-\:V:@R<@7V0'P9A0USQ=GWWRRD
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MMI->0+K'&2 -S2O:R)J?RIJAKUK-DJBRO5H4L_4:^M2H@4[[:<AU5[ 3><!
M).[H4>=84;^-!NSU*TS]@M:OLIZC.^%H_E]MZ%;+L9:L.X*'+['TR=84;^-!
MNSU*TS]@M-E/49WPM'\OMO0IL9:L.X*'+['TR=84;^-!NSU*TS]@M-E/49WP
MM'\OMO0IL9:L.X*'+['TR=84;^-!NSU*TS]@M-E/49WPM'\OMO0IL9:L.X*'
M+['TR=84;^-!NSU*TS]@M-E/49WPM'\OMO0IL9:L.X*'+['TR=84;^-!NSU*
MTS]@M-E/49WPM'\OMO0IL9:L.X*'+['TR=84;^-!NSU*TS]@M-E/49WPM'\O
MMO0IL9:L.X*'+['TR=84;^-!NSU*TS]@M-E/49WPM'\OMO0IL9:L.X*'+['T
MR=84;^-!NSU*TS]@M-E/49WPM'\OMO0IL9:L.X*'+['TR=84;^-!NSU*TS]@
MM-E/49WPM'\OMO0IL9:L.X*'+['TR=84;^-!NSU*TS]@M-E/49WPM'\OMO0I
ML9:L.X*'+['TR=84;^-!NSU*TS]@M-E/49WPM'\OMO0IL9:L.X*'+['TR=84
M;^-!NSU*TS]@M-E/49WPM'\OMO0IL9:L.X*'+['TR=84;^-!NSU*TS]@M-E/
M49WPM'\OMO0IL9:L.X*'+['TR=84;^-!NSU*TS]@M-E/49WPM'\OMO0IL9:L
M.X*'+['TRVN/OL)0@X<A^);<ZZ+9:R"V2D4TBA?%3+"REK6Q6T1A?*W-O:_+
M:U[?\.7EKVLF:L\@98IU:M@M56JRB\4WEUEKTH>6AP %1C2<#I&"\?*6H_+V
M2:E.E;;+3IOJL-1@;:;/4EH<6R2RH0,1H.*V#O,4^,=N/U;T7]A=>GKYD[A7
M\54]5>=K)E'@6\;2]=.\Q3XQVX_5O1?V%TU\R=PK^*J>JFLF4>!;QM+UT[S%
M/C';C]6]%_8737S)W"OXJIZJ:R91X%O&TO73O,4^,=N/U;T7]A=-?,G<*_BJ
MGJIK)E'@6\;2]=.\Q3XQVX_5O1?V%TU\R=PK^*J>JFLF4>!;QM+UT[S%/C';
MC]6]%_8737S)W"OXJIZJ:R91X%O&TO73O,4^,=N/U;T7]A=-?,G<*_BJGJIK
M)E'@6\;2]=9@=").52S79<1&X54TU+I999 =#)\F=L<<[VY%-'8WO^]SQORV
MMR>_R<O+:]?=9;70MC'5*#BYK77"2TMVT Q#@#H(Q7Q6FR5[&]M.NP,<YM\
M.:Z6R1,M)&D'!9#JTF?QA-O^A=!_8?7TKYDZM)G\83;_ *%T']A]$3JTF?QA
M-O\ H70?V'T1.K29_&$V_P"A=!_8?1$ZM)G\83;_ *%T']A]$3JTF?QA-O\
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MM4L63W&:=&F&,MEJ:,9:ZT%E&STCN5'E]1VEM*[MUXUMRJVBXTK.!5JMP<[
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M_.2_0:41*(E$2B)1$HBL'HC[\I_^ 3_[EJZ?U-].6?%D_P"^VKF_5!_\H_\
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%R?FO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g453477g71b77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g453477g71b77.jpg
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M 0$! 0$!_\  $0@ 00#W P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
M   *!@<("00%"P$" __$ #T0  $$ @(! P," P0&"P    ,! @0%!@< "!$2
M$Q0)%2$B,0H6%R,D,D$8-U%Q=;0S-#A"5G)VE+.UUO_$ !P! 0 " P$! 0
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M*L(X"K1N1RC>+XD^-7.E#^L7U-D#EQA,W8PVMW(/JI+9F,9;MF50RF28,LB
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MZX\C1]_;\:P= HC8*4NJ$>ON 2P!\=FWWO8]O?\ "K,X?$JY?<&037XXZ8[
MGV<F4^I:Q*P(&XLZ)=O'\?\ NZ0S7\@T<"C_ +NLB0#V/T*)4L-_),G02#*%
MS=RQ0H@GWWF8WH>VWS^/N+:JKMOX^*MR\[JOV$<+]>N<6%])%),\A@ [*J+,
MI<:X_"(VNF*+KX>;KQ\:K(Z^W=;U&]*;4XJ6M-6V:UJ$M2&E).%\Z 66_P!
MFN^.OH<-&-]2?EJ^5_/*E:].03]-7&<-Q,LT(FU %3MGMRB,;8CEY!V?QJVW
M74<\'4MO@Q;PM#,8=SEG[@[D1D.E!X^"-#\*XNW=\V^)Y;6:WU[C@,JSJQ9'
M>0,MQE@P72V*:)%='CGB%/))%3YT@A)L*+!A.%(*8C2$^/[P73,%]8S9?*W;
M66-B+ -'Q[D@C/%W#.LBJH?ZM (Y'EDY(J@@<_&=ZFGL;Z'$8JT6]R4O E9"
MW;C,@Y(A5&C+,4^L8F2-(XR'9B">-,4'8+/\;SFHP?=N&5>,EOW1QUMM3%=\
M4+YAEC1"R%^ZW4.5$?*\1Y)XU@)\!50D@#FH[QNW72V*N\9/DNG<A->"U#--
M!< <V$:\Y OU%M)&X3XT5XF$NB$;>JTK7JG*6F2@QO4>/ALS=%!#/;L>"F1N
M"%MSW$<B%_@=DE4Q>[*15^)6KJ&7'^,29;-&L&#!=Z#1$5Z5L6FA0)3T6&K7
M2HL:J,(+U3VV-NKA$%_;@6-64S5TC<A'!ON22#:OX[TEQ)(@^L\([SJS#W)M
M[?XOA;G9I,+;2)P:2<+VHHCID&^RMND;GZL@NB0,JG6@+B?X?B3AYIO\27U$
MG]9/J7;'SNOK'QM==JH8-\XE.&%4B.RFW<E9MJI?)1&C+;#S^'8Y7,"UJ$CU
M>:T3C>MTA#$AZL<3;37S7Q^[Y?P\?NK7)].;K<SM1V^U)K"SA+,PV+;NS?8K
M',5\=V#88C+BVKY:M\N&#))(J_$FE:GD4C( /\M1%<DYTYC1E<Q:6KKRA#]^
MY^[L0_&ZG\)"%AW\C(*A>I\I^B,+>W:MQG*>GMOO]1/\",OWF(%IM?,1&I=?
MU;=SV&F.D6PZS%!RG9MN234:(P>NJ0%-82YF?))CWL2KAPF/EEEK@]?DXJ]D
M(:F98/A()$>K$7KO5UZUE@[E8M]Z]*6$"J"69KC8D50/)/864+Q&^7'5<8Z-
ML5OL_;/,5[%BKY&X9R H6WT8V=F^$+ZAH2Q;QQY;J(YJ#ZAW9S36,0=73[G&
M=O:BIQ#KF:6W]AM3M# XT*$C@!J8L*_"E_10(8O<C K*.\JH<8:J)L5&L8UG
M([/J')V<2VK/'>6:#CZ+(0I=6X4> @60=R-5&P%CD0 >-5V:]Z:Q5]*UVJ2V
M5ZYYF^QT[VER6/GF6C/;D8G1+R1NQ/G>ZR KMO\ TL^P?IC;JZ\;&ZA9G,\-
M/L#K?DI,NUR^6OY^;9:WRB-/-CM4Q55JU.(4]K+>QJ(V<-[T(*06\Z6R'B]Q
MUSAYV][C&RF:VY>_)K:4,8T^7"%'.O9A\HYK+JW&^;')VV:@7VMLI$(;KC^R
MEU$5$C_Z<SH!^R?:I,O2BXZT9#U,CZ$%V7U3V=P6LQVVPB?92OMV(Y%8:UMP
M?::3'MB879W1KRLL:JBE Q"/.G@K"SZJLJ",C19B/8WIF$?&28@8_P#2=IE+
M=(W@9CQAD:V<<8X[B%W+JR(1"&8*654\!MURK/)E8LP<B<5>8JX>5)U4<IHD
MND/.22VG1!&Z/(#,54L%=W&RNC4/'O3U2ONF_9#.-.62RYF.!.W)-;W\IGAV
M2:\O#2"8_/>1&#&6? 4$K'[UPAL"E_36B1V_&]AS^/9W%28;)3V3<C&#W+:0
M_P [;R$]MOQ9=-&_L.XCZ\:KMG3^8CSF+M[Y>*RD=JZC7^:N8P.XNO)"ML21
M[.^VZ;\[K#_D/4U7H_\ \)UL^PS3Z:N88+92"%_H]V8V'C%&%SE<R+C648M@
M.PA#&BK^A"91E.6F<-J(WU$4GE7$=X5J3#3_ )@$_P 1_8*D\\5BK$CN-E/V
MC6T''1$],C+;L 2L\^%?5TWILI3D\?E?38)4-5/V5I%\K^R+>N@++OY>2[8;
M2QMV8'[IKC<*?AYB[Y_=X_"B]?WOI\1':*=/?7"JP^^&WU,_]4O8!_ ^:LH?
M;>I7]=FZJ',M/O3,8"J-^SG2+_,[)C,@*QLGU>E ON_<%\GPB*)ZD<B-56\L
M28+.CJO]-F.'TYO&\^H4OZ,Q^E'P:^T+?1X?M#0.]&JZV=P9Z4_0@DF]2+-?
M'IVX>L#BZ(#_ +)N-KSUY7R1HZJY77#)ON_7_-J$I/5(Q2-E448U7RK*ZUJI
M5K%>O^:(Z::T&U/V1 _A?\DA^KK/L=4XZZ4?#?/9.3\C+!,D#C]T:PD_BU3'
M2-YW^ELC:L?BL4O4 ^8BGA>=#^^1I@/P6OSTD8Q,3S8B-:CW9%!8Y_A/4YC*
MUKF-5?W5K%(16HOX17N5/\2\]?2,3Z['#?@6LI ^6S-Y.OQT-_D/NKY]'0'H
M,B=>3=Q@GYD"$$#]VSK\S5-:S1$[?Y]X1$_7EJ_C\?E20U5?]ZJJJO\ M5?/
M-K,>>@L7_N/\!(!_"M3#_P#CW*?[]_;'576NTL8Q[9F1T>F-5?S;L:6>SC9'
M=QROAQ'RW3F2K?WWI[[Y,<-FQC9TDY:F(R8U&BDD9[;B:,&%O;K#VEQU#F_0
MXF-87M+9P))!&(REOQ'PA6:$GMHHGD[9\H#L#>FS5E:YB[MNGL)Z[+.TR7=P
MC&-"_<#S\CIBZK/H2LQ@C#@!7(UNTL5^>F[3X-*V."JA9),? DK6TQ$+"K(#
MJVQ'$@M(A9*/*-!D(9R3)J.>5522Y%1@YUQC%Z*R28AIY+2,2IW;@:DFE[T3
M22$<4TIY *.W'H#[ ]S!QG)MUMC7RRPQW<G!^S;GE'#%V)Q'&#R?;#B68\Y-
MEOM?(5GFL<,KN7B SM:]C1TDAJ.1%1#1*:=+CN3S_P!YD@(GL7]T<U%3\IR/
MQSLGT?7Y4D$FY0Z_9DN(T<?D49@?PJ0R**_T@8\.-@+;./\ :C@E=#^YU4C\
MJK/NK&"_6^-2W-;\@&;1(XGJB>I RJ*^(=B+^Z->^)'<Y$_"J-OG]DY'?1V[
M#+W: GBV.=F'RY)<VP4_F [ ?F?W[_TB(IQ-FY^TN110?GQ>VN2P_>44_NJP
M?8.065J?K6<ZN<5V'6+'.=^7/]FJPL+7N5?RJN:-KE<OY<J^5_*\M'2J+'G.
MKE7PHOXB /8<I\@Q _(DC7RJL=5.TF$Z19O+''R D^YXPV"[/Y@;K8GF>.#R
M_"<BQ@B-7[Y03J\+G^/2*4>(](<C\_A'1Y?LG:J_A'#1514YR?'79L,C:7@W
M^K744K ?RD5QW%\?)X^2G\#76,C:"^QUW9G7ZS:RQ*3[!VC(C;^B_%OS%:[]
M>YV2DZU[AQLY'"L8%K%K8X"*K"M!F:@JI<9&JJ*GM#K;DY&^/*.>]KO\2<ZO
ME<8+GJ_ 7:CE%+ \SL!M2V/Y3H_](S6Z@^WL1\ZY1BLDUOTAG[-B1+%,D*H?
M!"Y K!(FO]$17#$?>2#[U?O7FGUR+J\+#T,.NM,R [*ARC-?[+9Y;&-84CS^
MAKB?'/75U5'D/:PA& *0@AO<UC%K&5SPM.LVO^)E@L&%D44CD8A"T5P%V0.:
MRRSL@) + !B-DU9\5@?5]&+8<A%-D$-ZKD'B)6E26V+:!/%HHH5<@$A22 =
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MZ3+T[QF/5OAU+>2C?N=B& _N'J/Z_'SKE?7,[49?I;L'TY@X :I_F74H[W?
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MW#@5]-D#([$+:%5U\ZYQ(O<7ZZ-=W&.W(2!Y:U;0G7_V]+-L_95)->6-<]Z
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ME:\CEFUOLAY JS$?,1.5<_@IK[U%)<Q=:6LMG'WKB-+22*'>N\41V:('Y&5
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B4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
